var title_f23_58_24480="Disk battery";
var content_f23_58_24480=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Disk battery lodged in the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An AP radiograph of an eight-month-old child with an opaque circular object in the esophagus. A) The \"halo\" lucency along the edge of the circular object suggests that the item has a bi-level contour consistent with a battery. The radiolucent trachea and bronchi are to the side and the orientation of the object suggests esophageal location. B) The lateral view also shows the bi-level contour of the object consistent with a battery.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24480=[""].join("\n");
var outline_f23_58_24480=null;
var title_f23_58_24481="Anhidrotic ectodermal dysplasia - teeth";
var content_f23_58_24481=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anhidrotic ectodermal dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Conical \"peg\" teeth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24481=[""].join("\n");
var outline_f23_58_24481=null;
var title_f23_58_24482="Cap polyposis Light";
var content_f23_58_24482=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Cap polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of cap polyposis showing elongated hyperplastic appearing glands and a cap of overyling mucosa composed of mucus, fibrin, and leukocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24482=[""].join("\n");
var outline_f23_58_24482=null;
var title_f23_58_24483="X-ray scaphoid fracture AP";
var content_f23_58_24483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    X-ray scaphoid fracture AP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP view of the left wrist (A, highlighted and magnified in B) reveals a complex fracture through the mid-portion of the scaphoid. The fracture fragments appear to be in anatomic alignment in this view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24483=[""].join("\n");
var outline_f23_58_24483=null;
var title_f23_58_24484="Scopolamine (ophthalmic): Drug information";
var content_f23_58_24484=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Scopolamine (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/8/4228?source=see_link\">",
"    see \"Scopolamine (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/56/9092?source=see_link\">",
"    see \"Scopolamine (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9522576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isopto&reg; Hyoscine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9923660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholinergic Agent;",
"     </li>",
"     <li>",
"      Anticholinergic Agent, Ophthalmic;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Mydriatic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9522658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Scopolamine hydrobromide:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Refraction:",
"     </i>",
"     Ophthalmic: Instill 1-2 drops to eye(s) 1 hour before procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Iridocyclitis:",
"     </i>",
"     Ophthalmic: Instill 1-2 drops to eye(s) up to 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9522659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9522699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrobromide [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isopto&reg; Hyoscine: 0.25% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9522586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9522670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Ophthalmic: Remove contact lenses prior to administration; wait 15 minutes before reinserting. To avoid excessive systemic absorption, finger pressure should be applied on the lacrimal sac for 2-3 minutes following application. Do not touch dropper to eye. Wash hands following administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9522587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Produce cycloplegia and mydriasis; treatment of iridocyclitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9522609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"     <b>",
"      Note:",
"     </b>",
"     Systemic adverse effects have been reported following ophthalmic administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, somnolence, visual hallucination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Eczematoid dermatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, edema, exudate, follicular conjunctivitis, increased intraocular pressure, local irritation, photophobia, vascular congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9522595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to scopolamine or any component of the formulation; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9522596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bacterial keratitis:  Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness and/or blurred vision, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery, driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Visual disturbances: Discontinue if patient reports unusual visual disturbances or pain within the eye.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For ophthalmic use only. To avoid precipitating angle closure glaucoma, an estimation of the depth of the anterior chamber angle should be made prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9522612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13872653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered intravenously or transdermally, scopolamine crosses the placenta; refer to Scopolamine (Systemic) monograph for details. Scopolamine is rapidly absorbed systemically after ocular application (Lahdes, 1990).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9522702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Isopto Hyoscine Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (5 mL): $38.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9522674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9522641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks the action of acetylcholine at parasympathetic sites in sphincter muscle of the iris and the accommodative muscle of the ciliary body; prevents accommodation; dilates pupils",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lahdes K, Huupponen R, Kaila T, et al. &ldquo;Systemic Absorption of Ocular Scopolamine in Patients,&rdquo;",
"      <i>",
"       J Ocul Pharmacol",
"      </i>",
"      , 1990 6(1):61-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/58/24484/abstract-text/2193993/pubmed\" id=\"2193993\" target=\"_blank\">",
"        2193993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9914 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24484=[""].join("\n");
var outline_f23_58_24484=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522576\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9923660\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522658\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522659\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522699\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522586\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522670\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522587\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522609\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522595\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522596\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300030\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522612\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13872653\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522702\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522674\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9522641\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9914\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9914|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/8/4228?source=related_link\">",
"      Scopolamine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/56/9092?source=related_link\">",
"      Scopolamine (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32375?source=related_link\">",
"      Scopolamine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/12/10437?source=related_link\">",
"      Scopolamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/0/39941?source=related_link\">",
"      Scopolamine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_58_24485="Basic case 5";
var content_f23_58_24485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Basic case 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 79px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24485=[""].join("\n");
var outline_f23_58_24485=null;
var title_f23_58_24486="Management of bronchopleural fistula in patients on mechanical ventilation";
var content_f23_58_24486=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of bronchopleural fistula in patients on mechanical ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24486/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24486/contributors\">",
"     David J Pierson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24486/contributors\">",
"     Andrew M Luks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24486/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24486/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24486/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24486/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/58/24486/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a pneumothorax is detected in a mechanically ventilated patient, air is evacuated from the pleural space by inserting a chest tube and applying external suction. The evacuated air is seen as bubbling through the water seal of the drainage device. Air may continue to leak into the pleural space for minutes to hours, but it will eventually stop in most cases. The bubbling ceases once the lung is fully reinflated and no further air leaks into the pleural space.",
"   </p>",
"   <p>",
"    A bronchopleural fistula (BPF) exists if the bubbling continues for 24 hours or more. It is indicative of a persistent air leak into the pleural space. Most are small and consist of only a few bubbles escaping through the water seal of the drainage device in synchrony with the inspiratory phase of the ventilator. However, a few leaks are larger and persist through both inspiration and expiration; the volume of such leaks may reach several hundred milliliters per breath.",
"   </p>",
"   <p>",
"    Assessment and management of a BPF in the setting of mechanical ventilation are reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The pathogenesis, management, and outcomes of BPF following lung surgery are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=see_link\">",
"     \"Sequelae and complications of pneumonectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many potential causes of BPF in mechanically ventilated patients. These include airway disruption or alveolar rupture prior to the initiation of mechanical ventilation (eg, trauma, surgery), laceration of the airway or visceral pleura during mechanical ventilation (eg, central line placement, thoracentesis), and spontaneous alveolar rupture (eg, a complication of the underlying disease or mechanical ventilation). The potential causes of BPF are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef79654 \" href=\"UTD.htm?26/19/26939\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Alveolar rupture due to mechanical ventilation appears to be a consequence of alveolar overdistension due to an excessive inflation volume, more than a consequence of increased airway pressure. This was shown by an animal study in which a high peak inflation volume without increased airway pressure caused alveolar injury, whereas high airway pressure without an increased inflation volume did not cause alveolar injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/4\">",
"     4",
"    </a>",
"    ]. The former conditions were created by high tidal volume external negative-pressure ventilation, while the latter conditions were created by strapping the chest and not allowing it to expand despite high inflation pressure. This animal data is supported by the observation that humans frequently have high airway pressures (eg, coughing, bronchospasm without air trapping), but alveolar rupture rarely results. In light of this evidence, the term \"volutrauma\" is a more accurate description of the pathogenesis of a pneumothorax as a complication of mechanical ventilation than &ldquo;barotrauma&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/5\">",
"     5",
"    </a>",
"    ]. The likelihood of volutrauma is increased in the presence of acute lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28519?source=see_link\">",
"     \"Inflammatory mechanisms of lung injury during mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While volume is probably the major factor in the development of a BPF, a large transpulmonary pressure gradient (ie, the difference in the airway and pleural pressures) may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/7\">",
"     7",
"    </a>",
"    ]. This may seem to contradict the observation above that high airway pressures are common but alveolar rupture seldom results. The difference is that high airway pressures are usually associated with a high pleural pressure (eg, coughing), so the transpulmonary pressure gradient remains small. However, if airway pressures increase and the pleural pressure remains low, a large transpulmonary pressure gradient develops that can contribute to alveolar rupture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We advocate the following approach to prevent ventilator-associated pneumothorax and BPF (",
"    <a class=\"graphic graphic_table graphicRef74558 \" href=\"UTD.htm?4/15/4348\">",
"     table 2",
"    </a>",
"    ). This approach is based upon the physiological data described in the previous section and clinical reasoning, which suggest that minimizing the tidal volume and plateau airway pressure during mechanical ventilation may reduce alveolar overdistention, alveolar rupture, pneumothorax, and BPF. Data from randomized trials have not shown that lung-protective ventilation decreases the incidence of ventilator-associated pneumothorax and BPF, but such evidence is limited by imprecise estimates due to the paucity of events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For all mechanically ventilated patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitor for the development of intrinsic positive end-expiratory pressure (ie, auto-PEEP). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H15#H15\">",
"       \"Positive end-expiratory pressure (PEEP)\", section on 'Assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoid hyperventilation because this may contribute to the development of auto-PEEP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H10#H10\">",
"       \"Positive end-expiratory pressure (PEEP)\", section on 'Causes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If auto-PEEP develops, treat it as described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H16#H16\">",
"       \"Positive end-expiratory pressure (PEEP)\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Monitor the static respiratory system compliance (tidal",
"      <span class=\"nowrap\">",
"       volume/plateau",
"      </span>",
"      airway pressure) whenever extrinsic positive end-expiratory pressure (ie, applied PEEP) is used. Decrease the level of applied PEEP if the static respiratory system compliance begins to decrease as the applied PEEP is increased.",
"     </li>",
"     <li>",
"      Separate the patient from mechanical ventilation as soon as possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=see_link\">",
"       \"Weaning from mechanical ventilation: Readiness testing\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients at high risk for alveolar rupture (eg, acute lung injury [ALI], acute respiratory distress syndrome [ARDS], obstructive lung disease, cavitary disease):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use tidal volumes &le;6",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of predicted body weight.",
"     </li>",
"     <li>",
"      Use applied PEEP cautiously.",
"     </li>",
"     <li>",
"      Use extreme care when inserting a subclavian or internal jugular central venous catheter, or performing a thoracentesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MEASURING THE LEAK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of the air leak through a BPF can be quantified using either a pneumotachograph or a water-filled spirometer (ie, devices for recording the rate of airflow to and from the lungs) placed between the chest tube and the drainage device [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/8\">",
"     8",
"    </a>",
"    ]. A heated-wire or spinning-vane type of spirometer should NOT be used.",
"   </p>",
"   <p>",
"    Such quantification of the volume of the air leak is not necessary outside of the research setting because it does not influence clinical management. Instead, the severity of the air leak is generally stratified into three levels (from least to most severe):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bubbling during inspiration only",
"     </li>",
"     <li>",
"      Bubbling during both inspiration and expiration",
"     </li>",
"     <li>",
"      Bubbling during both inspiration and expiration, as well as a detectable difference in the inspired and expired tidal volumes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last category suggests that there is an air leak greater than 100 to 150 mL per breath following an appropriate correction for compressible volume. Although BPFs can theoretically cause hypercapnia due to loss of alveolar ventilation through the air leak, this is rare in clinical practice. This is probably because the leaked gas participates in gas exchange rather than being lost or wasted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/9\">",
"     9",
"    </a>",
"    ]. Intractable respiratory acidosis and other serious complications are more likely due to the lung disease than the BPF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1780997\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals of BPF management include treating the underlying lung disease and reducing the air leak through ventilator adjustments to minimize the tidal volume and plateau airway pressure. There is no moderate or high quality evidence that indicates that decreasing the air leak in this manner improves mortality or other clinical outcomes, but elimination or reduction of contributing factors makes it less likely that a new pneumothorax will develop or that the BPF will worsen and become physiologically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/1,2,10\">",
"     1,2,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1406320\">",
"    <span class=\"h2\">",
"     Ventilator management",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with a BPF, the ventilator should be adjusted to minimize both tidal volume and the plateau airway pressure, thereby minimizing alveolar distension and the transpulmonary pressure gradient, respectively (",
"    <a class=\"graphic graphic_table graphicRef66471 \" href=\"UTD.htm?18/26/18860\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce the number of full ventilator-delivered breaths. This may be achieved by using pressure support ventilation (PSV) or a low rate of synchronized intermittent mandatory ventilation (SIMV), rather than using assist control ventilation (ACV), pressure control ventilation (PCV), or a high rate of SIMV.",
"     </li>",
"     <li>",
"      Decrease the tidal volume of each ventilator-delivered breath (5 to 8",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      predicted body weight for most patients, &le;6",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      predicted body weight for high risk patients such as those with acute lung injury [ALI], acute respiratory distress syndrome [ARDS], obstructive lung disease, or cavitary disease).",
"     </li>",
"     <li>",
"      Set a high inspiratory flow rate (eg, 70 to 100",
"      <span class=\"nowrap\">",
"       L/min),",
"      </span>",
"      thereby decreasing the inspiratory to expiratory ratio.",
"     </li>",
"     <li>",
"      Apply the least amount of chest tube suction necessary to maintain lung inflation.",
"     </li>",
"     <li>",
"      Wean and extubate patients as soon as the clinical circumstances allow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The rationale for many of the adjustments (eg, decrease the tidal volume, decrease the inspiratory to expiratory ratio, decrease the respiratory rate) is to prevent the development of intrinsic positive end-expiratory pressure (auto PEEP), since auto-PEEP increases the transpulmonary pressure gradient. When such adjustments are not possible or insufficient, a strategy of permissive hypercapnia is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=see_link\">",
"     \"Permissive hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports have described the use of alternative modes of mechanical ventilation, including independent lung ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], high-frequency ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], or airway pressure release ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/17\">",
"     17",
"    </a>",
"    ] when severe BPF persisted despite the conservative measures noted above, but there is no moderate or high quality evidence to suggest that these strategies are effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5591?source=see_link\">",
"     \"High-frequency ventilation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1406328\">",
"    <span class=\"h2\">",
"     Adjunctive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the alternative modes of mechanical ventilation described in the previous section, a wide variety of non-ventilator techniques have been used in an attempt to decrease the air leak in patients with BPF (",
"    <a class=\"graphic graphic_table graphicRef75185 \" href=\"UTD.htm?16/4/16460\">",
"     table 4",
"    </a>",
"    ). Most of these have been tried in the context of a postoperative BPF rather than a ventilator-associated BPF and there is a paucity of evidence supporting their efficacy. The techniques include chest tube occlusion during inspiration, the application of PEEP to the chest tube, and bronchoscopic occlusion of the affected airway using the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A balloon (using a Fogarty or Swan-Ganz catheter) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A plug composed of Gelfoam, fibrin, autologous clot, or tissue glue [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An endobronchial one-way valve [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/11,24,25\">",
"       11,24,25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An expandable endobronchial stent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Local application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"       silver nitrate",
"      </a>",
"      during a series of procedures",
"     </li>",
"     <li>",
"      Local injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/6/110?source=see_link\">",
"       polidocanol",
"      </a>",
"      sclerosants during a series of procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Coagulation of the injured site with the Nd:YAG laser (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=see_link\">",
"       \"Bronchoscopic laser resection\"",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases of severe, persistent BPFs associated with adverse clinical consequences, bronchoscopic approaches can be considered if there is a single leak site and a bronchoscopist with appropriate experience is available. These approaches become logistically difficult or impossible as the number",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    size of the air leaks increases; thus, in situations of massive air leaks, the ventilator strategies described in the previous section are preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20975623\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A BPF is usually a manifestation of the underlying lung disease, particularly in acute respiratory distress syndrome (ARDS). Therefore, measures to reduce the air leak are generally unsuccessful until the patient's underlying lung disease has improved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Even if the severity of the air leak is successfully reduced, there tends to be little effect on gas exchange, as measured by arterial blood gases. This is probably because the leaked gas participates in gas exchange rather than being lost or wasted, as suggested by a study in ARDS that found that the carbon dioxide content of the leaked gas was similar to that of gas that was exhaled via the endotracheal tube [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/9\">",
"     9",
"    </a>",
"    ]. A BPF rarely causes intractable respiratory acidosis; patients who fail to survive die with the BPF and not because of the BPF [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24486/abstract/29\">",
"     29",
"    </a>",
"    ]. Once the underlying lung disease improves and there is a diminished need for mechanical ventilation, the BPF nearly always resolves without specific therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1781043\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a pneumothorax is detected in a mechanically ventilated patient, air is evacuated from the pleural space by inserting a chest tube and applying external suction. The evacuated air is seen bubbling through the water seal of a drainage device. A bronchopleural fistula (BPF) exists if the bubbling continues for 24 hours or more. It is indicative of a persistent air leak into the pleural space. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many potential causes of BPF in mechanically ventilated patients. These include airway disruption or alveolar rupture prior to the initiation of mechanical ventilation (eg, trauma, surgery), laceration of the airway or visceral pleura (eg, central line placement, thoracentesis), and spontaneous alveolar rupture (eg, a complication of the underlying disease or mechanical ventilation). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanical ventilator settings that minimize the tidal volume and plateau airway pressure may reduce the incidence of pneumothorax and BPF, but definitive evidence is lacking. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The severity of the air leak can be categorized as bubbling during inspiration only, bubbling during both inspiration and expiration, or bubbling during both inspiration and expiration with a detectable difference in the inspired and expired tidal volumes. BPFs that fall into the last category can have physiological effects (eg, tachypnea, hypercapnia, hypoxemia), but significant harms (eg, death, persistent respiratory failure) seldom occur. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Measuring the leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with a BPF, we suggest using a mechanical ventilation strategy that minimizes both alveolar distension and the transpulmonary pressure gradient (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This may involve reducing the number of full ventilator-delivered breaths, decreasing the tidal volume of each ventilator-delivered breath, decreasing the inspiratory to expiratory ratio, applying the least amount of chest tube suction necessary to maintain lung inflation, and weaning patients as soon as the clinical circumstances allow. (See",
"      <a class=\"local\" href=\"#H1780997\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A BPF is usually a manifestation of the underlying lung disease. Therefore, measures to reduce the air leak are generally unsuccessful until the patient's underlying lung disease has improved. Once the underlying lung disease improves and there is a diminished need for mechanical ventilation, the BPF nearly always resolves without specific therapy. (See",
"      <a class=\"local\" href=\"#H20975623\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/1\">",
"      Kempainen RR, Pierson DJ. Persistent air leaks in patients receiving mechanical ventilation. Semin Respir Crit Care Med 2001; 22:675.",
"     </a>",
"    </li>",
"    <li>",
"     Luks AM, Pierson, DJ. Barotrauma and bronchopleural fistula. In: Principles and Practice of Mechanical Ventilation, 23rd ed, Tobin MJ.  (Ed), McGraw-Hill, New York 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/3\">",
"      Puskas JD, Mathisen DJ, Grillo HC, et al. Treatment strategies for bronchopleural fistula. J Thorac Cardiovasc Surg 1995; 109:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/4\">",
"      Dreyfuss D, Soler P, Basset G, Saumon G. High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure. Am Rev Respir Dis 1988; 137:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/5\">",
"      Dreyfuss D, Saumon G. Barotrauma is volutrauma, but which volume is the one responsible? Intensive Care Med 1992; 18:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/6\">",
"      Dreyfuss D, Soler P, Saumon G. Mechanical ventilation-induced pulmonary edema. Interaction with previous lung alterations. Am J Respir Crit Care Med 1995; 151:1568.",
"     </a>",
"    </li>",
"    <li>",
"     Doelken P, Sahn SA. Pleural Disease in the Critically Ill Patient. In: Intensive Care Medicine, 6th, Irwin RS, Rippe JM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.625.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/8\">",
"      Larson, RP, Capps, JS, Pierson, DJ. A comparison of three devices used for quantitating bronchopleural air leak. Respir Care 1986; 31:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/9\">",
"      Bishop MJ, Benson MS, Pierson DJ. Carbon dioxide excretion via bronchopleural fistulas in adult respiratory distress syndrome. Chest 1987; 91:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/10\">",
"      Litmanovitch M, Joynt GM, Cooper PJ, Kraus P. Persistent bronchopleural fistula in a patient with adult respiratory distress syndrome. Treatment with pressure-controlled ventilation. Chest 1993; 104:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/11\">",
"      Charan NB, Carvalho CG, Hawk P, et al. Independent lung ventilation with a single ventilator using a variable resistance valve. Chest 1995; 107:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/12\">",
"      Cheatham ML, Promes JT. Independent lung ventilation in the management of traumatic bronchopleural fistula. Am Surg 2006; 72:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/13\">",
"      Santini M, Vicidomini G, La Monica G, Pastore V. Use of a modified endobronchial tube for mechanical ventilation of patients with bronchopleural fistula. Eur J Cardiothorac Surg 2005; 28:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/14\">",
"      Galvin I, Krishnamoorthy R, Saad RS. Management of advanced ARDS complicated by bilateral pneumothoraces with high-frequency oscillatory ventilation in an adult. Br J Anaesth 2004; 93:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/15\">",
"      Ha DV, Johnson D. High frequency oscillatory ventilation in the management of a high output bronchopleural fistula: a case report. Can J Anaesth 2004; 51:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/16\">",
"      Campbell D, Steinmann M, Porayko L. Nitric oxide and high frequency jet ventilation in a patient with bilateral bronchopleural fistulae and ARDS. Can J Anaesth 2000; 47:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/17\">",
"      Darwish RS, Gilbert TB, Fahy BG. Management of a bronchopleural fistula using differential lung airway pressure release ventilation. J Cardiothorac Vasc Anesth 2003; 17:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/18\">",
"      Varoli F, Roviaro G, Grignani F, et al. Endoscopic treatment of bronchopleural fistulas. Ann Thorac Surg 1998; 65:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/19\">",
"      Lois M, Noppen M. Bronchopleural fistulas: an overview of the problem with special focus on endoscopic management. Chest 2005; 128:3955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/20\">",
"      McCormick BA, Wilson IH, Berrisford RG. Bronchopleural fistula complicating group A beta-haemolytic streptococcal pneumonia. Use of a Fogarty embolectomy catheter for selective bronchial blockade. Intensive Care Med 1999; 25:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/21\">",
"      Sprung J, Krasna MJ, Yun A, et al. Treatment of a bronchopleural fistula with a Fogarty catheter and oxidized regenerated cellulose (surgicel). Chest 1994; 105:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/22\">",
"      Nicholas JM, Dulchavsky SA. Successful use of autologous fibrin gel in traumatic bronchopleural fistula: case report. J Trauma 1992; 32:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/23\">",
"      Baumann WR, Ulmer JL, Ambrose PG, et al. Closure of a bronchopleural fistula using decalcified human spongiosa and a fibrin sealant. Ann Thorac Surg 1997; 64:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/24\">",
"      Travaline JM, McKenna RJ Jr, De Giacomo T, et al. Treatment of persistent pulmonary air leaks using endobronchial valves. Chest 2009; 136:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/25\">",
"      Abu-Hijleh M, Blundin M. Emergency use of an endobronchial one-way valve in the management of severe air leak and massive subcutaneous emphysema. Lung 2010; 188:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/26\">",
"      Takahashi M, Takahashi H, Itoh T, et al. Ultraflex expandable stents for the management of air leaks. Ann Thorac Cardiovasc Surg 2006; 12:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/27\">",
"      Martin WR, Siefkin AD, Allen R. Closure of a bronchopleural fistula with bronchoscopic instillation of tetracycline. Chest 1991; 99:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/28\">",
"      Wang KP, Schaeffer L, Heitmiller R, Baker R. NdYAG laser closure of a bronchopleural fistula. Monaldi Arch Chest Dis 1993; 48:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24486/abstract/29\">",
"      Pierson DJ, Horton CA, Bates PW. Persistent bronchopleural air leak during mechanical ventilation. A review of 39 cases. Chest 1986; 90:321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1649 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-4FABCF92AE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24486=[""].join("\n");
var outline_f23_58_24486=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1781043\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEASURING THE LEAK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1780997\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1406320\">",
"      Ventilator management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1406328\">",
"      Adjunctive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20975623\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1781043\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1649|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/19/26939\" title=\"table 1\">",
"      Mechanisms of barotrauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/15/4348\" title=\"table 2\">",
"      Prevention of barotrauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/26/18860\" title=\"table 3\">",
"      Mechanical vent in BP fistula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/4/16460\" title=\"table 4\">",
"      Treatment of BP fistula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38645?source=related_link\">",
"      Bronchoscopic laser resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/29/5591?source=related_link\">",
"      High-frequency ventilation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28519?source=related_link\">",
"      Inflammatory mechanisms of lung injury during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=related_link\">",
"      Permissive hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32329?source=related_link\">",
"      Sequelae and complications of pneumonectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21112?source=related_link\">",
"      Weaning from mechanical ventilation: Readiness testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_58_24487="Cryopyrin-associated periodic syndromes and related disorders";
var content_f23_58_24487=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cryopyrin-associated periodic syndromes and related disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24487/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24487/contributors\">",
"     Peter A Nigrovic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24487/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24487/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24487/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24487/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24487/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/58/24487/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three clinically overlapping, interleukin-1-associated, autoinflammatory disorders are known collectively as the cryopyrin-associated periodic syndromes (CAPS) or cryopyrinopathies: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal onset multisystem inflammatory disorder (NOMID, also known as chronic infantile neurological cutaneous and articular [CINCA] syndrome). A related but distinct autoinflammatory disorder is due to deficiency of the interleukin-1-receptor antagonist (DIRA).",
"   </p>",
"   <p>",
"    There are a number of other periodic autoinflammatory disorders that often present with periodic fever. These disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;All three cryopyrinopathies arise from mutations in a single gene, NLRP3 (also called CIAS1) at chromosome 1q44, encoding a protein called cryopyrin (also known as NALP3 and PYPAF1; cryopyrin is derived from the Greek words for icy cold and fire) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The mode of inheritance is autosomal dominant with variable penetrance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathogenesis of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryopyrin is important in innate immunity as part of the multiprotein inflammasome complex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/4\">",
"     4",
"    </a>",
"    ]. It belongs to a family of NLR (nucleotide-binding domain and leucine-rich-repeat containing) proteins that respond to intracellular pathogens and other danger signals.",
"   </p>",
"   <p>",
"    Cryopyrin serves as a scaffold for assembly of the inflammasome complex that is responsible, through a cascade of interactions involving caspase 1, for activation of the potent proinflammatory cytokines interleukin (IL)-1 beta and IL-18, through cleavage of their inactive precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal signals for cryopyrin activation include the various PAMPs (pathogen-associated molecular patterns, such as muramyl dipeptides, bacterial or viral RNA); DAMPs (danger-associated molecular patterns, such as uric acid crystals, ATP, low intracellular concentrations of potassium, skin irritants, ultraviolet B radiation); and possibly alum, the commonly used vaccine adjuvant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Point mutations in NLRP3 in the cryopyrinopathies are thought to promote aberrant formation of the inflammasome and inappropriate production of active IL-1 beta, possibly due to defective self-inhibition by the mutant cryopyrin protein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenotypic differences among the cryopyrin-associated periodic syndromes probably reflect in large part the differential impact of mutations on the activity of the inflammasome, modulated by individual genetic background. Not surprisingly, the boundaries between these three syndromes are not sharp, and patients may have features of more than one disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Familial cold autoinflammatory syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial cold autoinflammatory syndrome (FCAS), formerly called familial cold urticaria, is the mildest of the cryopyrin-associated disorders. It is an unusual condition in which exposure to generalized cold, such as an air-conditioned room, results in a stereotyped systemic inflammatory response including fever, an urticarial rash, conjunctival injection, and substantial arthralgias.",
"   </p>",
"   <p>",
"    Symptoms usually develop in the first year of life, occasionally in the newborn period upon exposure to cold in the delivery room. Urticaria followed by fever starts about seven hours after cold exposure. Leukocytosis, sometimes to above",
"    <span class=\"nowrap\">",
"     30,000/microL,",
"    </span>",
"    starts about 10 hours after cold exposure and begins to subside 12 to 14 hours later [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Attacks usually resolve within 24 hours, though considerable variability is observed between individuals and also depends on the extent and duration of cold exposure. The presence of conjunctivitis helps to discriminate FCAS from other periodic fever disorders. Patients may experience daily rashes, fatigue, headache, and myalgias, particularly toward afternoon and evening, even in the absence of cold exposure.",
"   </p>",
"   <p>",
"    Histologically, the rash in these patients is characterized by a marked infiltration of neutrophils, in contrast to other causes of urticaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=see_link\">",
"     \"Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uncommonly, chronic untreated FCAS leads to secondary AA amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Treatment of FCAS and other cryopyrinopathies is discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Treatment of cryopyrinopathies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Muckle-Wells syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muckle-Wells syndrome (MWS) is a rare condition characterized by the following triad [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/1,12,15,16\">",
"     1,12,15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intermittent episodes of fever, headache, urticarial rash, and joint pain (arthralgias or arthritis)",
"     </li>",
"     <li>",
"      Progressive sensorineural hearing loss",
"     </li>",
"     <li>",
"      Secondary (AA) amyloidosis with nephropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Febrile episodes occur at irregular intervals every few weeks, lasting 12 to 36 hours before resolving spontaneously. Age of onset is variable. Precipitating factors vary and cannot always be identified, but they may include both heat and cold [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The sensorineural hearing loss, presumably related to inflammation within the cochlea or the leptomeninges, begins in childhood and may be profound [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amyloidosis occurs in a subset of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/12,14,20,21\">",
"     12,14,20,21",
"    </a>",
"    ]. The signs and symptoms of amyloidosis in the cryopyrinopathies are similar to those observed with secondary amyloidosis in other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=see_link&amp;anchor=H10#H10\">",
"     \"An overview of amyloidosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NLRP3 mutations implicated in MWS may be distinct or overlap those causing FCAS [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Familial cold autoinflammatory syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neonatal onset multisystem inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in cryopyrin are responsible for some, but not all, cases of neonatal-onset multisystem inflammatory disease (NOMID), which is also known as chronic infantile neurological cutaneous and articular (CINCA) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. It is the most serious of the autoinflammatory cryopyrinopathies.",
"   </p>",
"   <p>",
"    Clinical features, including a migratory, erythematous rash resembling urticaria, fever, impaired growth, abnormal facies with frontal bossing, protruding eyes, and saddle-shaped nose, are characteristic and generally develop at or near the time of birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/9,23\">",
"     9,23",
"    </a>",
"    ]. Other manifestations are chronic meningitis, sensorineural hearing loss, cerebral atrophy, uveitis, lymphadenopathy, and hepatosplenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/19\">",
"     19",
"    </a>",
"    ]. Limb and joint pain is common and exuberant cartilaginous proliferation at growth plates and epiphyses resemble tumors. NOMID may cause premature death, and chronic inflammation may lead to AA amyloidosis. Images and links to additional images of the rash and other findings associated with these conditions can be found at the website of the NOMID Alliance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15076366\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cryopyrinopathies are rare, with an estimated prevalence in a study in France of 1 in 360,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/25\">",
"     25",
"    </a>",
"    ]. Diagnosis is made by genetic testing for NALP3 mutations. The diagnosis should be suspected in patients with recurrent episodes of unexplained systemic inflammation, with fever present in most, but not all, patients. A family history is common, since these diseases are autosomal dominant, but sporadic cases may occur. Urticaria is a hallmark symptom that occurs rarely in other autoinflammatory syndromes, but it is not present in all CAPS patients. In an analysis of over 800 samples sent for NALP3 testing, a positive test was unlikely in a patient without at least three episodes of recurrence, age at presentation &lt;20 years, and elevation in the C-reactive protein [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment of cryopyrinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central role for IL-1 beta in these disorders is confirmed by the effectiveness of therapies directed against IL-1 in preventing and alleviating symptoms and substantially reducing levels of inflammatory indices, including serum amyloid A [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis of disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anakinra",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with functional cold autoinflammatory syndrome (FCAS), treatment with the IL-1 receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , given SQ on a daily basis, can prevent cold-induced attacks and markedly reduce daily symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Among patients with renal AA amyloidosis due to CAPS, anakinra has led to marked reductions in proteinuria and stabilization of serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/13,30\">",
"     13,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=see_link\">",
"     \"Renal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    can also control systemic inflammation in Muckle-Wells syndrome (MWS), potentially with an effect on amyloid risk mediated through normalization of levels of serum amyloid A protein. The impact on hearing loss remains uncertain, but partial recovery has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/16,31-34\">",
"     16,31-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In",
"    <span class=\"nowrap\">",
"     NOMID/CINCA,",
"    </span>",
"    treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    has improved signs and symptoms related to inflammation in some [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/35-40\">",
"     35-40",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/38\">",
"     38",
"    </a>",
"    ], cases. Bone and joint abnormalities are less responsive to this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rilonacept (IL-1 trap)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"     rilonacept",
"    </a>",
"    , an IL-1 trap given by weekly SQ injections, can markedly reduce symptoms and inflammatory markers, including serum CRP and SAA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Two double blind, placebo controlled trials of 6 and 18 weeks duration examined the effects of rilonacept in 41 patients with FCAS and three with MWS. The treated patients experienced a significant reduction in symptom scores compared with placebo (84 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/42\">",
"     42",
"    </a>",
"    ]. The drug was well tolerated, and the most common adverse effects were injection site reactions (36 versus 13 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Canakinumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     Canakinumab",
"    </a>",
"    is a human anti-IL-1 beta monoclonal antibody that does not react with other members of the IL-1 family. Subcutaneous administration of canakinumab to 35 patients with CAPS who required treatment resulted in a complete response in 34 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/43\">",
"     43",
"    </a>",
"    ]. Of the responders, 31 were randomly assigned to receive canakinumab or placebo every eight weeks for up to 24 weeks. Treated patients were more likely to remain in remission (100 versus 19 percent) and to normalize their serum C-reactive protein and serum amyloid A protein levels.",
"   </p>",
"   <p>",
"    Benefit was sustained in an open-label extension. The median time to flare in the placebo-treated patients was approximately 22 weeks after the initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"     canakinumab",
"    </a>",
"    given prior to randomization. The incidence of suspected infections was significantly higher in the canakinumab-treated patients during the randomized phase of the trial (67 versus 25 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports suggest that other drugs may be effective in patients with",
"    <span class=\"nowrap\">",
"     NOMID/CINCA,",
"    </span>",
"    including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/44\">",
"     44",
"    </a>",
"    ] and a humanized anti-interleukin-6 receptor monoclonal antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DEFICIENCY OF THE IL-1-RECEPTOR ANTAGONIST (DIRA)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An autoinflammatory syndrome distinct from the cryopyrinopathies is characterized by the neonatal onset of sterile multifocal osteomyelitis, periostitis, and a neutrophilic pustulosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The disease presents at birth or within two months postpartum. Other clinical findings include periarticular swelling from epiphyseal overgrowth, oral mucosal lesions, and vasculitis. Untreated patients may die from multiorgan failure. Marked elevations of the erythrocyte sedimentation rate and serum C-reactive protein are present, but fever is not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 10 patients described in the two initial reports all exhibited deficiency of the interleukin (IL)-1-receptor antagonist (IL-1RN) due to homozygous germ-line mutations in",
"    <em>",
"     IL1RN",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Eight of these patients had single point mutations, and two had deletions within the sequence encoding IL-1RN. Two additional patients, both Puerto Rican, were reported with a homozygous microdeletion of",
"    <em>",
"     IL1RN",
"    </em>",
"    and five adjacent related genes, a deletion common in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The clinical syndrome is thought to be due to hyperresponsiveness to IL-1 beta stimulation because of failure of the defective protein to be secreted. Heterozygous carriers are asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24190861\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is made by genetic testing for mutations involving",
"    <em>",
"     IL1RN",
"    </em>",
"    . The differential diagnosis includes infantile pustulosis (neonatal onset pustulosis), infantile pustular psoriasis, and SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=see_link\">",
"     \"Neutrophilic dermatoses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with nonsteroidal antiinflammatory drugs, disease-modifying antirheumatic drugs, and glucocorticoids were only partially effective. As expected from the pathophysiology,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    , a recombinant human IL-1 receptor antagonist, was highly effective in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24487/abstract/45,46,48\">",
"     45,46,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H281165075\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three clinically overlapping autoinflammatory disorders are known collectively as the cryopyrin-associated periodic syndromes (CAPS) or cryopyrinopathies: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal onset multisystem inflammatory disorder (NOMID, also known as chronic infantile neurological cutaneous and articular [CINCA] syndrome). The CAPS all arise from point mutations in a single gene, NLRP3, which encodes the cryopyrin protein. Cryopyrin is important in innate immunity as part of the multiprotein inflammasome complex. Inheritance of these disorders is autosomal dominant with variable penetrance. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Cryopyrin-associated periodic syndromes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NLRP3 mutations are thought to promote aberrant formation of the inflammasome and inappropriate production of active IL-1 beta. Phenotypic differences among CAPS are thought to largely reflect the differential impact of mutations on the activity of the inflammasome, modulated by individual genetic background. The syndromes may overlap and patients may have features of more than one disorder. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial cold autoinflammatory syndrome (FCAS), formerly called familial cold urticaria, is the mildest of the cryopyrin-associated disorders. It is an unusual condition in which exposure to generalized cold, such as an air-conditioned room, results in a stereotyped systemic inflammatory response including fever, an urticarial rash, conjunctival injection, and substantial arthralgias. Symptoms usually develop in the first year of life. Attacks usually resolve within 24 hours, though considerable variability is observed. The presence of conjunctivitis helps to discriminate FCAS from other periodic fever disorders. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Familial cold autoinflammatory syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Muckle-Wells syndrome (MWS) is a rare condition characterized by the triad of intermittent episodes of fever, headache, urticarial rash, and joint pain (arthralgias or arthritis); progressive sensorineural hearing loss; and secondary (AA) amyloidosis with nephropathy. Febrile episodes occur at irregular intervals every few weeks, lasting 12 to 36 hours before resolving spontaneously. Age of onset is variable. Precipitating factors vary and cannot always be identified, but they may include both heat and cold. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Muckle-Wells syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abnormalities in cryopyrin are responsible for some, but not all, cases of neonatal-onset multisystem inflammatory disease (NOMID), which is also known as chronic infantile neurological cutaneous and articular (CINCA) syndrome. Clinical features, including a migratory, erythematous rash resembling urticaria, fever, impaired growth, abnormal facies with frontal bossing, protruding eyes, and saddle-shaped nose, are characteristic and generally develop at or near the time of birth. Other manifestations affecting the brain, eyes, joints, liver, and spleen may also be present, and AA amyloidosis can occur. NOMID may cause premature death. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neonatal onset multisystem inflammatory disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A central role for IL-1 beta in these disorders is confirmed by the effectiveness of therapies directed against IL-1 in preventing and alleviating symptoms and in substantially reducing levels of inflammatory indices, including serum amyloid A. These therapies include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/21/16724?source=see_link\">",
"       rilonacept",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41796?source=see_link\">",
"       canakinumab",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment of cryopyrinopathies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Anakinra'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Rilonacept (IL-1 trap)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Canakinumab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An autoinflammatory syndrome distinct from the cryopyrinopathies is characterized by the neonatal onset of sterile multifocal osteomyelitis, periostitis, a neutrophilic dermatosis, and elevated acute phase reactants without fever. Untreated patients may die from multiorgan failure. The patients have a deficiency of the interleukin (IL)-1-receptor antagonist (IL-1RN) due to homozygous germ-line mutations, which may result in hyperresponsiveness to IL-1 beta stimulation and the clinical syndrome. The most effective treatment has been with the interleukin-1 receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Deficiency of the IL-1-receptor antagonist (DIRA)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Genetics'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/1\">",
"      Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/2\">",
"      Kastner DL, O'Shea JJ. A fever gene comes in from the cold. Nat Genet 2001; 29:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/3\">",
"      Neven B, Callebaut I, Prieur AM, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCU. Blood 2004; 103:2809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/4\">",
"      Neven B, Prieur AM, Quartier dit Maire P. Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 2008; 4:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/5\">",
"      Drenth JP, van der Meer JW. The inflammasome--a linebacker of innate defense. N Engl J Med 2006; 355:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/6\">",
"      Eisenbarth SC, Colegio OR, O'Connor W, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008; 453:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/7\">",
"      Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003; 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/8\">",
"      Aksentijevich I, D Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/9\">",
"      Hull KM, Shoham N, Chae JJ, et al. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003; 15:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/10\">",
"      Tindall JP, Beeker SK, Rosse WF. Familial cold urticaria. A generalized reaction involving leukocytosis. Arch Intern Med 1969; 124:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/11\">",
"      Doeglas HM, Bleumink E. Familial cold urticaria. Clinical findings. Arch Dermatol 1974; 110:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/12\">",
"      Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/13\">",
"      Thornton BD, Hoffman HM, Bhat A, Don BR. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007; 49:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/14\">",
"      van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/15\">",
"      MUCKLE TJ. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962; 31:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/16\">",
"      Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/17\">",
"      Muckle TJ. The 'Muckle-Wells' syndrome. Br J Dermatol 1979; 100:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/18\">",
"      Montealegre Sanchez GA, Hashkes PJ. Neurological manifestations of the Mendelian-inherited autoinflammatory syndromes. Dev Med Child Neurol 2009; 51:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/19\">",
"      Ahmadi N, Brewer CC, Zalewski C, et al. Cryopyrin-associated periodic syndromes: otolaryngologic and audiologic manifestations. Otolaryngol Head Neck Surg 2011; 145:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/20\">",
"      Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun 2004; 5:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/21\">",
"      Dod&eacute; C, Cuisset L, Delpech M, Grateau G. TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis. J Nephrol 2003; 16:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/22\">",
"      Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46:3340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/23\">",
"      Goldfinger S. The inherited autoinflammatory syndrome: a decade of discovery. Trans Am Clin Climatol Assoc 2009; 120:413.",
"     </a>",
"    </li>",
"    <li>",
"     www.nomidalliance.net/index.html (Accessed on February 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/25\">",
"      Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011; 70:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/26\">",
"      Gattorno M, Martini A. Treatment of autoinflammatory syndromes. Curr Opin Pediatr 2010; 22:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/27\">",
"      Maksimovic L, Stirnemann J, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 2008; 47:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/28\">",
"      Ross JB, Finlayson LA, Klotz PJ, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008; 12:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/29\">",
"      Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/30\">",
"      Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006; 142:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/31\">",
"      Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348:2583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/32\">",
"      Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/33\">",
"      Mirault T, Launay D, Cuisset L, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006; 54:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/34\">",
"      Yamazaki T, Masumoto J, Agematsu K, et al. Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 2008; 58:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/35\">",
"      Matsubayashi T, Sugiura H, Arai T, et al. Anakinra therapy for CINCA syndrome with a novel mutation in exon 4 of the CIAS1 gene. Acta Paediatr 2006; 95:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/36\">",
"      Seitz M, Kamgang RK, Simon HU, Villiger PM. Therapeutic interleukin (IL) 1 blockade normalises increased IL1 beta and decreased tumour necrosis factor alpha and IL10 production in blood mononuclear cells of a patient with CINCA syndrome. Ann Rheum Dis 2005; 64:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/37\">",
"      Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 2005; 44:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/38\">",
"      Matsubara T, Hasegawa M, Shiraishi M, et al. A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. Arthritis Rheum 2006; 54:2314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/39\">",
"      Caroli F, Pontillo A, D'Osualdo A, et al. Clinical and genetic characterization of Italian patients affected by CINCA syndrome. Rheumatology (Oxford) 2007; 46:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/40\">",
"      Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/41\">",
"      Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/42\">",
"      Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/43\">",
"      Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/44\">",
"      Kallinich T, Hoffman HM, Roth J, Keitzer R. The clinical course of a child with CINCA/NOMID syndrome improved during and after treatment with thalidomide. Scand J Rheumatol 2005; 34:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/45\">",
"      Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/46\">",
"      Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/47\">",
"      Minkis K, Aksentijevich I, Goldbach-Mansky R, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol 2012; 148:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/48\">",
"      Brau-Javier CN, Gonzales-Chavez J, Toro JR. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Arch Dermatol 2012; 148:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/49\">",
"      Minkis K, Aksentijevich I, Goldbach-Mansky R, et al. Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis. Arch Dermatol 2012; 148:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24487/abstract/50\">",
"      Cowen EW, Goldbach-Mansky R. DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name? Arch Dermatol 2012; 148:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5585 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24487=[""].join("\n");
var outline_f23_58_24487=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H281165075\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathogenesis of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Familial cold autoinflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Muckle-Wells syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neonatal onset multisystem inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15076366\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment of cryopyrinopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anakinra",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rilonacept (IL-1 trap)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Canakinumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DEFICIENCY OF THE IL-1-RECEPTOR ANTAGONIST (DIRA)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24190861\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H281165075\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1530?source=related_link\">",
"      An overview of amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30010?source=related_link\">",
"      Chronic urticaria: Clinical manifestations, diagnosis, pathogenesis, and natural history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30393?source=related_link\">",
"      Neutrophilic dermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/29/13784?source=related_link\">",
"      Renal amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_58_24488="Screening for abdominal aortic aneurysm";
var content_f23_58_24488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for abdominal aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24488/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24488/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24488/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24488/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24488/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24488/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/58/24488/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aneurysm is a focal dilation of a blood vessel with respect to the original or adjacent artery. An abdominal aortic aneurysm (AAA) is defined as a dilated aorta with a diameter at least 1.5 times the diameter measured at the level of the renal arteries. In most individuals, the diameter of the normal abdominal aorta is approximately 2.0 cm (range 1.4 to 3.0 cm). For practical purposes, an AAA is diagnosed when the aortic diameter exceeds 3.0 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of aneurysms never rupture, but when they do, sudden death from retroperitoneal or intraperitoneal exsanguination is usual unless surgery is performed immediately. Acute AAA rupture is one of the most dramatic emergencies in medicine, particularly because it often masquerades as another problem. In the United States, ruptured AAA is estimated to cause 4 to 5 percent of sudden deaths and is the thirteenth most common cause of death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increasing use of computed tomography and magnetic resonance imaging has revealed asymptomatic and previously undiagnosed AAAs. The concern raised by people who become incidentally aware of a \"ticking bomb\" in their abdomen presents a common dilemma to clinicians. The decision to perform elective surgery to prevent aneurysm rupture must be weighed against immediate surgical risks in an often older adult population and the low likelihood that a rupture will occur before death from other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/4\">",
"     4",
"    </a>",
"    ]. The trade-off between present and future risk should involve patient preference as an important consideration in the decision to screen for an AAA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dilemmas associated with the incidental discovery of an AAA make decisions regarding screening difficult. Systematic population screening would yield many previously undiagnosed small aneurysms that are unlikely to rupture, resulting in needless disease labeling [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/5\">",
"     5",
"    </a>",
"    ]. Only aneurysms of a certain size would be considered for surgery, with smaller aneurysms subject to watchful waiting.",
"   </p>",
"   <p>",
"    Issues related to screening for AAAs will be reviewed here. Details regarding the clinical manifestations, diagnosis, and treatment of AAAs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology and risk factors related to abdominal aortic aneurysm (AAA) are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link&amp;anchor=H1460375#H1460375\">",
"     \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H1382371318#H1382371318\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In summary, the most important risk factors for AAA are increasing age, smoking, and male sex:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of AAAs is negligible in individuals under the age of 60, particularly women, but then increases dramatically with age [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/1,6,7\">",
"       1,6,7",
"      </a>",
"      ]. Screening studies show that AAA occurs in 4 to 9 percent of individuals over the age of 60 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. However, most (57 to 88 percent) of these aneurysms are &le;3.5 cm in diameter. Clinically important aneurysms over 4.0 cm in diameter are present in about 1 percent of men between the ages of 55 and 64; the prevalence increases by 2 to 4 percent per decade thereafter [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. On the basis of population surveillance data over 20 years from a screening program in Gloucestershire, United Kingdom, it appears that the mean aortic diameter and incidence of aortic aneurysm in men has been declining since the program inception in 1990 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It has been estimated that smoking accounts for 75 percent of all aneurysms &ge;4.0 cm in diameter [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/13\">",
"       13",
"      </a>",
"      ]. Studies indicate that the prevalence of AAA in individuals over 65 years appears to be decreasing [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/14,15\">",
"       14,15",
"      </a>",
"      ], and this decrease has been correlated with trends in cigarette smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AAAs are four to six times more common in men than in women [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. In addition, AAAs develop in women about ten years later than in men [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/19\">",
"       19",
"      </a>",
"      ]. A model to identify women with multiple cardiovascular risk factors who are at particularly high risk for AAA and may benefit from screening has been developed combining two US data sets, but remains to be validated in other populations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A positive family history is another factor that significantly increases the risk of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/21\">",
"     21",
"    </a>",
"    ]. In a study that did not have a clear definition of a positive family history, a patient report of a positive family history doubled the risk for AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/21\">",
"     21",
"    </a>",
"    ]. A clear history of surgery for an AAA in a first-degree relative may increase the risk four-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a number of other predictors of AAA have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/13,20\">",
"     13,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      White race",
"     </li>",
"     <li>",
"      Atherosclerosis, especially peripheral artery disease",
"     </li>",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Aneurysms of the femoral or popliteal arteries",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regular exercise and a diet rich in fruit, vegetables, and nuts reduce the risk of AAA [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observations have been noted regarding the natural history of abdominal aortic aneurysms (AAAs) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H431203144#H431203144\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Aneurysm diameter and rupture risk'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only 1 percent of 65-year-old men who have a negative ultrasound will develop an AAA in the next five years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aneurysms less than 4.0 cm in transverse diameter are unlikely to rupture in the next five years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/24,25\">",
"       24,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The five-year overall cumulative rupture rate of incidentally diagnosed aneurysms in population-based samples is 25 to 40 percent for aneurysms larger than 5.0 cm, compared with 1 to 7 percent for aneurysms 4.0 to 5.0 cm [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/24,26-28\">",
"       24,26-28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management options for patients with an asymptomatic AAA include surgery, endovascular stenting, and watchful waiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link\">",
"     \"Endovascular repair of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H611107773#H611107773\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The case-fatality rate is 50 percent when surgery is performed emergently on the 40 percent of patients with ruptured aneurysms who survive long enough to come to medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. This contrasts with mortality for elective repair that is reported to be between 1 and 5 percent, depending upon comorbidities and the type of repair [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=see_link&amp;anchor=H53322839#H53322839\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SCREENING TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic abdominal aortic aneurysms (AAAs) can be detected on physical examination or by imaging studies. Abdominal ultrasonography is considered the screening modality of choice for AAAs because of its high sensitivity and specificity, as well as its safety and relatively low cost.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abdominal ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography has been used as the screening modality in the large randomized trials of screening for AAA. With a sensitivity of 95 to 100 percent and a specificity of nearly 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/32\">",
"     32",
"    </a>",
"    ], ultrasonography has superb test characteristics for diagnosing and following an AAA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H22322286#H22322286\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Imaging asymptomatic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aorta bifurcates at the umbilicus. Thus, physical examination in a patient with an AAA may reveal a pulsatile mass in the epigastrium. The accuracy of the clinical examination is markedly diminished by obese body habitus and smaller aneurysm size [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/33\">",
"     33",
"    </a>",
"    ]. The reproducibility of physical examination findings between clinicians has not been studied. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H181174645#H181174645\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Abdominal palpation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of abdominal palpation for screening purposes has been evaluated in several populations. One report of asymptomatic, high-risk internal medicine clinic attendees found an aneurysm prevalence of 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/34\">",
"     34",
"    </a>",
"    ]. Using ultrasonography as the gold standard, the sensitivity of abdominal palpation varies from 23 to 68 percent, and specificity from 75 to 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Sensitivity increases with the size of the aneurysm and decreased abdominal girth. In one study, the sensitivity was 61 percent for AAAs 3.0 to 3.9 cm, 69 percent for aneurysms 4.0 to 4.9 cm, and 82 percent for aneurysms 5.0 cm or greater; when girth was less than 100 cm, sensitivity was 100 percent for aneurysms 5.0 cm or larger [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/36\">",
"     36",
"    </a>",
"    ]. The predictive value of palpation declines dramatically below age 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;AAAs may be seen on plain films of the abdomen, abdominal computed tomography (CT), and magnetic resonance imaging (MRI). Both CT and MRI appear to be highly accurate tests for AAAs but are not generally performed for screening as they are more expensive than abdominal ultrasonography. However, nearly two-thirds of aneurysms leading to surgery are detected as incidental findings on imaging studies (most often CT or MRI) that are performed for other indications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H15828721#H15828721\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS OF SCREENING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of population-based screening for abdominal aortic aneurysms (AAAs) with abdominal ultrasonography has been evaluated in large randomized trials and systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/17,21,39-44\">",
"     17,21,39-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Multicenter Aneurysm Screening Study (MASS), the largest of the randomized trials, evaluated a population-based sample of 67,800 men between the ages of 65 and 74 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/39\">",
"     39",
"    </a>",
"    ]. Subjects were randomly assigned to receive an invitation to undergo ultrasound screening or no correspondence. Of the 33,839 men invited to undergo screening, 80 percent were tested. The prevalence of aortic aneurysms (defined as maximum aortic diameter &ge;3.0 cm) was 4.9 percent (1333 aneurysms). Repeat ultrasonography was performed yearly in those with an aortic diameter of 3.0 to 4.4 cm and every three months with an aortic diameter of 4.5 to 5.4 cm. Patients were referred for urgent surgery at an aortic diameter &ge;5.5 cm, an increase in aortic diameter by more than 1 cm in a year, or symptoms attributed to the aneurysm. Surgery was performed significantly more often in the screened group (354 versus 146 patients in the control group).",
"   </p>",
"   <p>",
"    A decrease in aneurysm-related deaths (30-day mortality from surgery and deaths from ruptured aneurysms) for the screened group, compared with the control group, was seen at four-year follow-up (0.49 versus 0.85 per 1000 person years, hazard ratio [HR] 0.58, 95% CI 0.42-0.78) and sustained with follow-up through 7, 10, and 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. Significant reductions in all-cause mortality (HR 0.96, 95% CI 0.93-1.00) as well as AAA-related mortality were first demonstrable at the seven-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/45\">",
"     45",
"    </a>",
"    ]. In the final data analysis from this trial, at 13 years, there was a 42 percent reduction (95% CI 31-51 percent) in aneurysm-related deaths, with an estimation of 216 men needing to be invited for screening to save one death over 13 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/47\">",
"     47",
"    </a>",
"    ]. The overall reduction in all-cause mortality was 3 percent (CI 1-5 percent). There were twice as many elective operations for AAA and half as many emergency operations in the invited group compared to the control group. Among 25,541 men with a normal first scan, there were a total of 59 ruptured abdominal aneurysms, with most ruptures occurring after eight years of follow-up and in men whose initial scan showed an aortic diameter 2.5 to 2.9 cm; whether rescreening is indicated for this population at some subsequent interval (possibly six to seven years after the initial examination) would require further investigation. Additionally, it should be noted that the rate of ruptured aortic aneurysm in the population has been declining since the initiation of MASS, even in the absence of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two meta-analyses analyzed four randomized trials of population based screening for AAA in people over age 65, including the four-year followup data from the MASS trial [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/21,43\">",
"     21,43",
"    </a>",
"    ]. Both analyses concluded that an invitation to attend a screening for AAA significantly reduces the risk of AAA-related mortality by about 50 percent in men. A post-hoc analysis in one study found a significant reduction in AAA-related mortality in men ages 65 to 74 (OR 0.19, 95% CI 0.04-0.89) but not in men ages 75 to 83 (OR 1.13, 0.56-2.29) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/40\">",
"     40",
"    </a>",
"    ]. An updated meta-analysis analyzed the four randomized trials, including ten-year outcome data for the MASS trial, and also found a 45 percent reduction in AAA-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/49\">",
"     49",
"    </a>",
"    ]. This analysis additionally found a strong trend toward reduction in all-cause mortality (HR 0.98, 95% CI 0.96 to 1.00) for men over age 65 who were invited for screening.",
"   </p>",
"   <p>",
"    Results 20 years after initiation of a screening program for 65 year old men in Gloucestershire, England, are available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/12\">",
"     12",
"    </a>",
"    ]. Nearly 62,000 men were invited for screening, and 85 percent participated. One hundred and forty-eight of 52,690 screenees had an initial aortic diameter &gt;5.4 cm and were referred for treatment; 4.6 percent had a diameter 2.6 to 5.4 cm and underwent surveillance. Perioperative mortality for the 631 surgeries performed on screen-detected aneurysms was 3.9 percent; an additional 372 procedures were performed for aneurysms detected incidentally with a perioperative mortality of 6.7 percent. The number of ruptured aneurysms fell annually during the course of the program in Gloucestershire.",
"   </p>",
"   <p>",
"    Only one study examined population-based screening in women, a population in whom the prevalence of AAA is significantly lower than in men (1.3 versus 7.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/17\">",
"     17",
"    </a>",
"    ]. Screening had no effect on AAA-related mortality (OR 1.0, 95% CI 0.14-7.07) or all-cause mortality (OR 1.05, 0.92-1.19) at five-year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/17\">",
"     17",
"    </a>",
"    ] and 10-year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early cost-effectiveness analysis, based upon relatively short-term (four-year) follow-up of the MASS trial data, suggested a high cost for a quality-adjusted life-year (QALY) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/51\">",
"     51",
"    </a>",
"    ]. Subsequent data indicate incremental cost-effectiveness with longer follow-up, as would be anticipated with major expense up front for surgical intervention, and sustained long-term benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/45,46,52\">",
"     45,46,52",
"    </a>",
"    ]. Cost-effectiveness based on seven-year follow-up in men was estimated at $19,500 per life-year gained based upon AAA mortality, and $7600 per life-year gained based on all cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/45\">",
"     45",
"    </a>",
"    ]. Cost-effectiveness was also demonstrated in a Danish screening trial involving men aged 64 to 73 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/52\">",
"     52",
"    </a>",
"    ] as well as in modeling studies for men age 65 in the Netherlands or Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Screening high-risk populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of rise in prevalence of AAAs with age is increased in people who have ever smoked, compared to nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/13\">",
"     13",
"    </a>",
"    ]. In a modeling study, inviting only those men aged 65 to 74 years with a history of ever smoking (accounting for 69 percent of men in this age group) for one time screening would account for 89 percent of the anticipated reduction in AAA-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/21\">",
"     21",
"    </a>",
"    ]. Modeling studies have also found that screening strategies that incorporate only the risk factors of age, sex, and lifetime smoking history outperform strategies that consider other risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HARM FROM SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal ultrasonography has no known inherent risks. Potential harms from screening for abdominal aortic aneurysm (AAA) include psychological distress and adverse outcomes from management of the AAA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychological distress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychologic harm from screening is of particular concern in patients found to have small AAAs that do not require immediate intervention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from Denmark, men found to have a small AAA on screening had lower quality of life (QOL) scores, mainly related to poorer health perception [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/54\">",
"       54",
"      </a>",
"      ]. During a period of conservative management, the QOL scores declined further, mainly due to worsening health perception and psychosomatic distress. The entire group of men who were attending screenings also had a lower QOL than the controls; however, once men were found to not have an AAA, their QOL increased beyond that of the controls, suggesting that screening caused transient anxiety even in healthy men.",
"     </li>",
"     <li>",
"      Six weeks after screening, participants in the MASS study who were found to have an AAA had slightly higher anxiety scores, slightly lower SF-36 mental and physical health scores, and lower self-rated health than participants whose screen result was negative [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these results suggest that screening for AAA produces mild transient anxiety in the people screened. Men found to have an AAA that does not require immediate intervention may experience declines in self-perceived health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of AAA repair are common and can be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=see_link\">",
"     \"Complications of endovascular abdominal aortic repair\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who undergo screening and are managed surgically are at risk for immediate harms (surgical complications, hospitalization, death) while harm from an AAA rupture would occur at some future point in time. The perioperative (30-day) mortality rate with elective AAA repair in major randomized trials varied from 2.7 to 5.8 percent, depending upon comorbidity factors and the type of procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A separate issue is the relative mortality in patients undergoing elective open surgery compared to endovascular repair. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link\">",
"     \"Endovascular repair of abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) makes the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men who are ages 65 to 75 and who have ever smoked should be screened one time for AAA by abdominal ultrasonography. The USPSTF found that there is little benefit to repeat screening in men who have a negative ultrasound and that men over age 75 are unlikely to benefit from screening.",
"     </li>",
"     <li>",
"      Because the prevalence of AAA is very low in men ages 65 to 75 who have never smoked, and thus any harms of screening are likely similar to the benefits, the USPSTF does not recommend for or against screening in such men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The USPSTF recommends against screening for AAA in women.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p>",
"    In 2005, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    published guidelines on peripheral artery disease in conjunction with major societies in vascular medicine, vascular surgery, and interventional radiology, including the Society for Vascular Surgery, the American Association of Vascular Surgery and the Society for Vascular Medicine and Biology [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/1\">",
"     1",
"    </a>",
"    ]. These guidelines included discussions on the diagnosis and management of AAA.",
"   </p>",
"   <p>",
"    With regard to screening, the following conclusions were reached:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It was recommended that men 60 years of age or older, who are either siblings or offspring of patients with AAAs should undergo physical examination and ultrasound screening for the detection of aortic aneurysms.",
"     </li>",
"     <li>",
"      It was considered reasonable that men who are 65 to 75 years of age who have ever smoked should undergo a physical examination and one-time ultrasound screening for detection of AAAs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The Canadian Society for Vascular Surgery recommends screening for men between age 65 and 75 who are candidates for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/59\">",
"     59",
"    </a>",
"    ]. Recommendations are not to screen women &gt;65 years on a population basis, but to individualize screening for women with multiple risks (smoking, cerebrovascular disease, and family history).",
"   </p>",
"   <p>",
"    In the United Kingdom, a National Health Service AAA Screening Program (NAAASP) has been funded to screen 65 year-old men for AAAs in England and is being implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Medicare coverage in the US",
"    </span>",
"   </p>",
"   <p>",
"    Medicare coverage for a one time ultrasound study was made available as of January 2007 for Medicare recipients who meet the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24488/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Referral from an initial \"Welcome to Medicare\" physical examination within six months of Medicare eligibility",
"     </li>",
"     <li>",
"      Males between 65 and 75 years of age who smoked at least 100 cigarettes",
"     </li>",
"     <li>",
"      Males or females with a family history of AAA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/39/22130?source=see_link\">",
"       \"Patient information: Abdominal aortic aneurysm (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=see_link\">",
"       \"Patient information: Abdominal aortic aneurysm (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Undetected abdominal aortic aneurysm (AAA) commonly presents catastrophically with fatal rupture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link\">",
"       \"Management of asymptomatic abdominal aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal ultrasonography is a highly sensitive and specific screening test for AAA. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Abdominal ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for AAA in men over age 65 results in a decreased risk of AAA-related mortality; however, any absolute benefit on overall mortality is likely to be small in people at no increased risk for AAA. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Effectiveness of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Screening for AAA can lead to psychological distress, particularly in those found to have small AAAs that will be managed conservatively. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Psychological distress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The perioperative (30-day) mortality rate with elective AAA repair in major randomized trials varied from 2.7 to 5.8 percent, depending upon comorbidity factors and the type of procedure. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In agreement with the recommendation of the USPSTF, we recommend one-time screening for AAA with abdominal ultrasonography in men ages 65 to 75 who have ever smoked (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Major society recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest one-time screening for AAA in men ages 65 to 75 who have never smoked but who have a first-degree relative who required repair of an AAA or died from a ruptured AAA (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Data for screening women with a family history are not as strong, and screening should be individualized based on other risk factors and patient preference. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=see_link&amp;anchor=H1460375#H1460375\">",
"       \"Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link&amp;anchor=H1382371318#H1382371318\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If endovascular repair of AAA is proven safer than open surgical repair while achieving similar effectiveness, the group of people for whom screening for AAA is beneficial would likely expand. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link&amp;anchor=H783678#H783678\">",
"       \"Management of asymptomatic abdominal aortic aneurysm\", section on 'Open versus endovascular aneurysm repair'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link\">",
"       \"Endovascular repair of abdominal aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/1\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/2\">",
"      Ouriel K, Green RM, Donayre C, et al. An evaluation of new methods of expressing aortic aneurysm size: relationship to rupture. J Vasc Surg 1992; 15:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/3\">",
"      Schermerhorn M. A 66-year-old man with an abdominal aortic aneurysm: review of screening and treatment. JAMA 2009; 302:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/4\">",
"      Welch HG, Albertsen PC, Nease RF, et al. Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med 1996; 124:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/5\">",
"      Melton, LJ, Bickerstaff, LK, Hollier, LH, et al. Changing incidence of abdominal aortic aneurysms: A population based study. Am J Epidemiol 1984; 120:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/6\">",
"      Singh K, B&oslash;naa KH, Jacobsen BK, et al. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study : The Troms&oslash; Study. Am J Epidemiol 2001; 154:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/7\">",
"      Powell JT, Greenhalgh RM. Clinical practice. Small abdominal aortic aneurysms. N Engl J Med 2003; 348:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/8\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997; 126:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/9\">",
"      Scott RA, Ashton HA, Kay DN. Abdominal aortic aneurysm in 4237 screened patients: prevalence, development and management over 6 years. Br J Surg 1991; 78:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/10\">",
"      Newman AB, Arnold AM, Burke GL, et al. Cardiovascular disease and mortality in older adults with small abdominal aortic aneurysms detected by ultrasonography: the cardiovascular health study. Ann Intern Med 2001; 134:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/11\">",
"      Collin J, Araujo L, Walton J, Lindsell D. Oxford screening programme for abdominal aortic aneurysm in men aged 65 to 74 years. Lancet 1988; 2:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/12\">",
"      Darwood R, Earnshaw JJ, Turton G, et al. Twenty-year review of abdominal aortic aneurysm screening in men in the county of Gloucestershire, United Kingdom. J Vasc Surg 2012; 56:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/13\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators. Arch Intern Med 2000; 160:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/14\">",
"      Svensj&ouml; S, Bj&ouml;rck M, G&uuml;rtelschmid M, et al. Low prevalence of abdominal aortic aneurysm among 65-year-old Swedish men indicates a change in the epidemiology of the disease. Circulation 2011; 124:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/15\">",
"      Norman PE, Spilsbury K, Semmens JB. Falling rates of hospitalization and mortality from abdominal aortic aneurysms in Australia. J Vasc Surg 2011; 53:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/16\">",
"      Lederle FA. The rise and fall of abdominal aortic aneurysm. Circulation 2011; 124:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/17\">",
"      Scott RA, Wilson NM, Ashton HA, Kay DN. Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study. Br J Surg 1995; 82:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/18\">",
"      Lederle FA, Johnson GR, Wilson SE, Aneurysm Detection and Management Veterans Affairs Cooperative Study. Abdominal aortic aneurysm in women. J Vasc Surg 2001; 34:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/19\">",
"      McFarlane MJ. The epidemiologic necropsy for abdominal aortic aneurysm. JAMA 1991; 265:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/20\">",
"      Kent KC, Zwolak RM, Egorova NN, et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 2010; 52:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/21\">",
"      Fleming C, Whitlock EP, Beil TL, Lederle FA. Screening for abdominal aortic aneurysm: a best-evidence systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2005; 142:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/22\">",
"      Salo JA, Soisalon-Soininen S, Bondestam S, Mattila PS. Familial occurrence of abdominal aortic aneurysm. Ann Intern Med 1999; 130:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/23\">",
"      Emerton ME, Shaw E, Poskitt K, Heather BP. Screening for abdominal aortic aneurysm: a single scan is enough. Br J Surg 1994; 81:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/24\">",
"      Nevitt MP, Ballard DJ, Hallett JW Jr. Prognosis of abdominal aortic aneurysms. A population-based study. N Engl J Med 1989; 321:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/25\">",
"      Katz DA, Littenberg B, Cronenwett JL. Management of small abdominal aortic aneurysms. Early surgery vs watchful waiting. JAMA 1992; 268:2678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/26\">",
"      Lederle FA, Johnson GR, Wilson SE, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002; 287:2968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/27\">",
"      Johansson G, Nydahl S, Olofsson P, Swedenborg J. Survival in patients with abdominal aortic aneurysms. Comparison between operative and nonoperative management. Eur J Vasc Surg 1990; 4:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/28\">",
"      Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. The UK Small Aneurysm Trial Participants. Lancet 1998; 352:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/29\">",
"      Farooq MM, Freischlag JA, Seabrook GR, et al. Effect of the duration of symptoms, transport time, and length of emergency room stay on morbidity and mortality in patients with ruptured abdominal aortic aneurysms. Surgery 1996; 119:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/30\">",
"      Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993; 328:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/31\">",
"      Thomas PR, Stewart RD. Abdominal aortic aneurysm. Br J Surg 1988; 75:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/32\">",
"      U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: recommendation statement. Ann Intern Med 2005; 142:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/33\">",
"      Chervu A, Clagett GP, Valentine RJ, et al. Role of physical examination in detection of abdominal aortic aneurysms. Surgery 1995; 117:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/34\">",
"      Lederle FA, Walker JM, Reinke DB. Selective screening for abdominal aortic aneurysms with physical examination and ultrasound. Arch Intern Med 1988; 148:1753.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Preventive Services Task Force.. Guide to clinical preventive services, 2nd ed, Williams &amp; Wilkins, Baltimore 1996. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/36\">",
"      Fink HA, Lederle FA, Roth CS, et al. The accuracy of physical examination to detect abdominal aortic aneurysm. Arch Intern Med 2000; 160:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/37\">",
"      Beede SD, Ballard DJ, James EM, et al. Positive predictive value of clinical suspicion of abdominal aortic aneurysm. Implications for efficient use of abdominal ultrasonography. Arch Intern Med 1990; 150:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/38\">",
"      Kahn CE Jr, Quiroz FA. Positive predictive value of clinical suspicion for abdominal aortic aneurysm. Implications for use of ultrasonography. J Gen Intern Med 1996; 11:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/39\">",
"      Ashton HA, Buxton MJ, Day NE, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet 2002; 360:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/40\">",
"      Norman PE, Jamrozik K, Lawrence-Brown MM, et al. Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm. BMJ 2004; 329:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/41\">",
"      Lindholt JS, Juul S, Fasting H, Henneberg EW. Hospital costs and benefits of screening for abdominal aortic aneurysms. Results from a randomised population screening trial. Eur J Vasc Endovasc Surg 2002; 23:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/42\">",
"      Lindholt JS, Juul S, Fasting H, Henneberg EW. Screening for abdominal aortic aneurysms: single centre randomised controlled trial. BMJ 2005; 330:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/43\">",
"      Cosford PA, Leng GC. Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev 2007; :CD002945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/44\">",
"      Scott RA. Priorities in the management of abdominal aortic aneurysm. Br J Surg 2007; 94:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/45\">",
"      Kim LG, P Scott RA, Ashton HA, et al. A sustained mortality benefit from screening for abdominal aortic aneurysm. Ann Intern Med 2007; 146:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/46\">",
"      Thompson SG, Ashton HA, Gao L, et al. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009; 338:b2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/47\">",
"      Thompson SG, Ashton HA, Gao L, et al. Final follow-up of the Multicentre Aneurysm Screening Study (MASS) randomized trial of abdominal aortic aneurysm screening. Br J Surg 2012; 99:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/48\">",
"      Darwood RJ, Brooks MJ. The impact of decreasing abdominal aortic aneurysm prevalence on a local aneurysm screening programme. Eur J Vasc Endovasc Surg 2012; 44:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/49\">",
"      Takagi H, Goto SN, Matsui M, et al. A further meta-analysis of population-based screening for abdominal aortic aneurysm. J Vasc Surg 2010; 52:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/50\">",
"      Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. Br J Surg 2002; 89:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/51\">",
"      Multicentre Aneurysm Screening Study Group. Multicentre aneurysm screening study (MASS): cost effectiveness analysis of screening for abdominal aortic aneurysms based on four year results from randomised controlled trial. BMJ 2002; 325:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/52\">",
"      Lindholt JS, S&oslash;rensen J, S&oslash;gaard R, Henneberg EW. Long-term benefit and cost-effectiveness analysis of screening for abdominal aortic aneurysms from a randomized controlled trial. Br J Surg 2010; 97:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/53\">",
"      Spronk S, van Kempen BJ, Boll AP, et al. Cost-effectiveness of screening for abdominal aortic aneurysm in the Netherlands and Norway. Br J Surg 2011; 98:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/54\">",
"      Lindholt JS, Vammen S, Fasting H, Henneberg EW. Psychological consequences of screening for abdominal aortic aneurysm and conservative treatment of small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2000; 20:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/55\">",
"      Huber TS, Wang JG, Derrow AE, et al. Experience in the United States with intact abdominal aortic aneurysm repair. J Vasc Surg 2001; 33:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/56\">",
"      Lederle FA, Wilson SE, Johnson GR, et al. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/57\">",
"      Lederle FA, Freischlag JA, Kyriakides TC, et al. Outcomes following endovascular vs open repair of abdominal aortic aneurysm: a randomized trial. JAMA 2009; 302:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/58\">",
"      United Kingdom Small Aneurysm Trial Participants. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24488/abstract/59\">",
"      Mastracci TM, Cin&agrave; CS, Canadian Society for Vascular Surgery. Screening for abdominal aortic aneurysm in Canada: review and position statement of the Canadian Society for Vascular Surgery. J Vasc Surg 2007; 45:1268.",
"     </a>",
"    </li>",
"    <li>",
"     NHS Abdominal Aortic Aneurysm Screening Programme. file://aaa,screening.nhs.uk (Accessed on July 11, 2012).",
"    </li>",
"    <li>",
"     www.cms.hhs.gov/MLNproducts/downloads/aaafinal5mar07.pdf (Accessed on December 12, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7569 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-110.170.48.130-F96105F60D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24488=[""].join("\n");
var outline_f23_58_24488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NATURAL HISTORY AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abdominal ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EFFECTIVENESS OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Screening high-risk populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HARM FROM SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychological distress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MAJOR SOCIETY RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Medicare coverage in the US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25626?source=related_link\">",
"      Complications of endovascular abdominal aortic repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=related_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11450?source=related_link\">",
"      Epidemiology, risk factors, pathogenesis and natural history of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=related_link\">",
"      Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/62/34787?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/39/22130?source=related_link\">",
"      Patient information: Abdominal aortic aneurysm (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_58_24489="Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features";
var content_f23_58_24489=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24489/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24489/contributors\">",
"     V Reid Sutton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24489/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24489/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24489/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24489/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24489/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/58/24489/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital metabolic disorders result from the absence or abnormality of an enzyme or its cofactor, leading to either accumulation or deficiency of a specific metabolite (",
"    <a class=\"graphic graphic_table graphicRef82924 \" href=\"UTD.htm?39/44/40651\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56040 \" href=\"UTD.htm?8/23/8572\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef69937 \" href=\"UTD.htm?8/13/8411\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74261 \" href=\"UTD.htm?21/62/22507\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef63392 \" href=\"UTD.htm?7/60/8140\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef86411 \" href=\"UTD.htm?24/12/24780\">",
"     table 6",
"    </a>",
"    ). Most of these disorders are transmitted as autosomal recessive traits.",
"   </p>",
"   <p>",
"    The possibility of an IEM should be considered in infants, children, and adults who present with any of the clinical or laboratory features discussed below or in the topic on metabolic emergencies, particularly if the findings remain unexplained after standard evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11382266\">",
"     'Age at presentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Optimal outcome for children with IEM depends upon recognition of the signs and symptoms of metabolic disease, and prompt evaluation and referral to a center familiar with the management of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/7\">",
"     7",
"    </a>",
"    ]. Delay in diagnosis may result in acute metabolic decompensation, progressive neurologic injury, or death.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, and most common chronic clinical and laboratory manifestations of IEM are discussed below. The presentation, initial diagnosis, and management of IEM presenting as metabolic emergencies are discussed in detail separately. The major classes of IEM and their characteristic clinical and biochemical features are described elsewhere, as is a diagnostic approach to identifying the specific IEM. In addition, many of the individual disorders are covered in separate topics (see specific topics). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=see_link\">",
"     \"Inborn errors of metabolism: Classification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=see_link\">",
"     \"Inborn errors of metabolism: Identifying the specific disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3709423\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual IEM are rare disorders, most having an incidence of less than 1 per 100,000 births. However, when considered collectively, the incidence may approach 1 in 800 to 2500 births [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one review of cases of IEM diagnosed in British Columbia (a predominantly Caucasian population) between 1969 and 1996, estimates of incidence of various classes of disorders were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Amino acid disorders (excluding phenylketonuria) &mdash; 7.6 per 100,000",
"     </li>",
"     <li>",
"      Lysosomal storage diseases &mdash; 7.6 per 100,000",
"     </li>",
"     <li>",
"      Phenylketonuria &mdash; 7.5 per 100,000",
"     </li>",
"     <li>",
"      Organic acidemias &mdash; 3.7 per 100,000",
"     </li>",
"     <li>",
"      Peroxisomal disorders &mdash; 3.5 per 100,000",
"     </li>",
"     <li>",
"      Mitochondrial diseases &mdash; 3.2 per 100,000",
"     </li>",
"     <li>",
"      Glycogen storage diseases &mdash; 2.3 per 100,000",
"     </li>",
"     <li>",
"      Urea cycle diseases &mdash; 1.9 per 100,000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another review of cases of IEM diagnosed in the West Midlands of the United Kingdom (where approximately 11 percent of the population is from black and ethnic minority groups), the frequency of selected IEM during 1999 to 2003 were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mitochondrial diseases &mdash; 20.3 per 100,000",
"     </li>",
"     <li>",
"      Lysosomal storage diseases &mdash; 19.3 per 100,000",
"     </li>",
"     <li>",
"      Amino acid disorders (excluding phenylketonuria) &mdash; 18.7 per 100,000",
"     </li>",
"     <li>",
"      Organic acidemias &mdash; 12.6 per 100,000",
"     </li>",
"     <li>",
"      Phenylketonuria &mdash; 8.1 per 100,000",
"     </li>",
"     <li>",
"      Peroxisomal disorders &mdash; 7.4 per 100,000",
"     </li>",
"     <li>",
"      Glycogen storage diseases &mdash; 6.8 per 100,000",
"     </li>",
"     <li>",
"      Urea cycle diseases &mdash; 4.5 per 100,000",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The greater incidence of disorders in the West Midlands study may be related to differences in the ethnicity of the populations, diagnostic methods and approaches between laboratories and countries, and improved technology, reporting, and awareness of some disorders (eg, mitochondrial disorders) over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3709430\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic disorders can be caused by several mechanisms. Most metabolic disorders are caused by a single enzyme deficiency that disrupts one step of a metabolic pathway. This disruption may lead to the accumulation of metabolites preceding the interrupted step, as in alkaptonuria, or the inability to make certain intermediates or end-products of a specific metabolic pathway, such as ketoacids during fasting in patients with medium chain acyl-CoA dehydrogenase (MCAD) deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less frequently, alterations that result in abnormalities of more than one enzyme can affect several metabolic steps. An example is multiple sulfatase deficiency, a lysosomal storage disorder that is caused by impaired posttranslational modification of sulfatases. Disorders of cofactors also can affect multiple enzymes. As an example, defects of cobalamin (vitamin B12) transport and synthesis may lead to accumulation of both methylmalonic acid and homocysteine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, metabolic disorders result from single mutations, deletions, or other genetic changes. However, a single enzyme, such as mitochondrial trifunctional protein, can be composed of multiple subunits encoded by different genes and catalyze more than one metabolic reaction. In addition, defects in different enzymes can result in a similar clinical phenotype (eg, elevated total plasma homocysteine may result from either deficiency of the enzyme cystathione beta-synthetase or from a cobalamin processing defect [complementation group G]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of IEM may include findings in virtually every system. Neurologic and gastrointestinal manifestations are the most frequent. The presenting features of IEM may be acute or chronic. Acute signs include episodic vomiting accompanied by dehydration or shock, lethargy and coma, rhabdomyolysis, and hypoglycemia associated with minor illnesses, stress, or a prolonged fast. Chronic signs of metabolic disease include growth",
"    <span class=\"nowrap\">",
"     delay/failure",
"    </span>",
"    to thrive, hepatomegaly, cardiomyopathy, spastic diplegia, and developmental delay or regression.",
"   </p>",
"   <p>",
"    Clinical presentations of metabolic emergencies, including recurrent vomiting and dehydration, lethargy and coma, seizures, and sudden infant death syndrome (SIDS) or apparent life-threatening event (ALTE) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H16728975#H16728975\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Clinical presentations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Neurologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic manifestations of IEM include lethargy, coma, seizures, developmental delay or regression, peripheral neuropathy, abnormalities of tone, motor problems, ataxia, and neuropsychiatric manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14590174\">",
"    <span class=\"h3\">",
"     Lethargy, coma, and seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;These neurologic presentations of IEM are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3681378#H3681378\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Lethargy and coma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3681503#H3681503\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Developmental delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that IEM are the underlying cause in only 1 to 5 percent of cases of developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, developmental delay",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intellectual disability (mental retardation), particularly with progressive worsening, may occur in all IEM. Thus, it is important to evaluate the possibility of IEM as an underlying cause to provide accurate prognosis, genetic counseling, and specific therapy if available [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=see_link&amp;anchor=H25935251#H25935251\">",
"     \"Inborn errors of metabolism: Identifying the specific disorder\", section on 'Developmental delay'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H22#H22\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'Follow-up medical evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=see_link&amp;anchor=H8#H8\">",
"     \"Intellectual disability (mental retardation) in children: Evaluation\", section on 'Metabolic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Developmental delay and intellectual disability are most commonly associated with the following metabolic disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Disorders of urea cycle and amino acid metabolism (",
"      <a class=\"graphic graphic_algorithm graphicRef73454 \" href=\"UTD.htm?6/26/6575\">",
"       algorithm 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Organic acidemias (",
"      <a class=\"graphic graphic_table graphicRef81144 \" href=\"UTD.htm?25/36/26187\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Disorders of creatine metabolism",
"     </li>",
"     <li>",
"      Peroxisomal disorders (",
"      <a class=\"graphic graphic_table graphicRef74261 \" href=\"UTD.htm?21/62/22507\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lysosomal storage disorders (",
"      <a class=\"graphic graphic_table graphicRef63392 \" href=\"UTD.htm?7/60/8140\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mitochondrial disorders and disorders of oxidative phosphorylation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Associated clinical findings may provide a clue to the underlying IEM. As examples, a family history of hearing loss and diabetes with maternal transmission in a patient with developmental delay is typical of a mitochondrial disorder, while spastic diplegia with developmental delay is suggestive of argininemia. Boolean searches of electronic resources, such as the Online Mendelian Inheritance in Man (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM\">",
"     www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM",
"    </a>",
"    ), using the signs and symptoms of an individual patient can be used to generate a differential diagnosis of IEM that could cause the observed signs and symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy may be a feature of disorders of vitamin B12 (cobalamin) transport and processing, lysosomal disorders (",
"    <a class=\"graphic graphic_table graphicRef63392 \" href=\"UTD.htm?7/60/8140\">",
"     table 5",
"    </a>",
"    ), and certain mitochondrial disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H15#H15\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Lysosomal storage diseases'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H20#H20\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Mitochondrial disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=see_link&amp;anchor=H24346287#H24346287\">",
"     \"Overview of acquired peripheral neuropathies in children\", section on 'Vitamin B12 (cobalamin) deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Abnormal tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotonia may be a manifestation of fatty acid oxidation disorders, mitochondrial disorders, urea cycle defects, peroxisomal disorders, lysosomal acid maltase deficiency (Pompe disease, glycogen storage disease II), and Smith-Lemli-Opitz syndrome (a disorder of cholesterol biosynthesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=see_link\">",
"     \"Approach to the infant with hypotonia and weakness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spastic diplegia may occur in arginase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myopathy and rhabdomyolysis can occur in lysosomal and nonlysosomal glycogen storage diseases, disorders of fatty acid oxidation, and mitochondrial disorders. Patients may complain of exercise intolerance, muscle pain, and cramps rather than weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=see_link&amp;anchor=H25935272#H25935272\">",
"     \"Inborn errors of metabolism: Identifying the specific disorder\", section on 'Skeletal myopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ataxia and dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ataxia may be a manifestation of peroxisomal disorders, mitochondrial disorders, and lysosomal storage disorders. Ataxia associated with a dysplastic cerebellum is seen in congenital disorders of glycosylation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link\">",
"     \"Peroxisomal disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H20#H20\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Mitochondrial disorders'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of the hereditary ataxias\", section on 'Mitochondrial ataxias'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the hereditary ataxias\", section on 'Sialidosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dystonia may be a feature of mitochondrial disorders or organic acidurias after a metabolic crisis associated with damage to the basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=see_link\">",
"     \"Classification and evaluation of dystonia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"     \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Neuropsychiatric",
"    </span>",
"    &nbsp;&mdash;&nbsp;IEM may present with psychiatric or behavioral manifestations, such as [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/10,15\">",
"     10,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-injurious behavior in Lesch-Nyhan syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H25#H25\">",
"       \"Hyperkinetic movement disorders in children\", section on 'Lesch-Nyhan syndrome'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Increased activity and aggression in Sanfilippo syndrome and other mucopolysaccharidoses (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Personality changes, deteriorating school performance, depression, paranoia, or catatonia in Wilson disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"       \"Epidemiology and pathogenesis of Wilson disease\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Psychosis, in some patients with adult Tay-Sachs disease, homocystinuria, the porphyrias, and purine disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal presentations of IEM include recurrent episodes of vomiting or dehydration, poor feeding, failure to thrive, decreased gastrointestinal motility, hepatomegaly or hepatosplenomegaly, and jaundice [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14590181\">",
"    <span class=\"h3\">",
"     Vomiting and poor feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent vomiting, poor feeding, and associated dehydration are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3681798#H3681798\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Gastrointestinal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Organomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatomegaly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    splenomegaly can be seen in the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glycogen storage diseases (GSD)",
"     </li>",
"     <li>",
"      Lysosomal storage diseases (Gaucher, Niemann-Pick)",
"     </li>",
"     <li>",
"      Galactosemia",
"     </li>",
"     <li>",
"      Peroxisomal disorders",
"     </li>",
"     <li>",
"      Tyrosinemia type 1",
"     </li>",
"     <li>",
"      Bile acid disorders",
"     </li>",
"     <li>",
"      Congenital disorders of glycosylation (CDGs, also referred to as carbohydrate deficient glycoprotein syndromes)",
"     </li>",
"     <li>",
"      Acid lipase deficiency (Wolman",
"      <span class=\"nowrap\">",
"       disease/cholesterol",
"      </span>",
"      ester storage disorder)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hepatosplenomegaly and isolated splenomegaly occur primarily in lysosomal storage disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/16\">",
"     16",
"    </a>",
"    ], whereas isolated hepatomegaly is more typical of glycogen storage diseases and certain mitochondrial diseases. In addition, signs or symptoms that accompany hepatosplenomegaly may suggest a particular diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatomegaly with hypoglycemia and poor growth is suggestive of glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease), glycogen debrancher deficiency (glycogen storage disease III, Cori disease, Forbes disease), disorders of gluconeogenesis, or severe hyperinsulinism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"       \"Approach to hypoglycemia in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"       \"Etiology of hypoglycemia in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link\">",
"       \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13861?source=see_link\">",
"       \"Glycogen debrancher deficiency (glycogen storage disease III)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatomegaly with liver failure suggests hereditary fructose intolerance, galactosemia, tyrosinemia type 1, neonatal hemochromatosis, a mitochondrial disorder, or Wilson disease [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/3,13\">",
"       3,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=see_link\">",
"       \"Etiology of hypoglycemia in infants and children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=see_link\">",
"       \"Clinical features and diagnosis of galactosemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"       \"Disorders of tyrosine metabolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link&amp;anchor=H23#H23\">",
"       \"Causes of neonatal cholestasis\", section on 'Gestational alloimmune liver disease (neonatal hemochromatosis)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gaucher disease should be suspected in a child of Ashkenazi Jewish ancestry with anemia and thrombocytopenia in addition to hepatosplenomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"       \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholestatic jaundice may be a manifestation of galactosemia, alpha-1 antitrypsin deficiency, disorders of bile acid metabolism, transaldolase deficiency, peroxisomal disorders, Niemann-Pick disease, neonatal hemochromatosis, and congenital disorders of glycosylation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link\">",
"     \"Causes of neonatal cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic or dilated cardiomyopathy may occur in several IEM and is typically related to impaired energy metabolism or storage material. Hypertrophic cardiomyopathy occurs in lysosomal acid maltase deficiency (GSD type II, Pompe disease) and in the mucopolysaccharidoses. Dilated cardiomyopathy can occur in fatty acid oxidation disorders, organic acidemias, and mitochondrial disorders (eg, disorders of oxidative phosphorylation). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"     \"Approach to the metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=see_link&amp;anchor=H25935265#H25935265\">",
"     \"Inborn errors of metabolism: Identifying the specific disorder\", section on 'Cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Dysmorphic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysmorphic features may be present at birth or may develop with age in a number of IEM, including [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peroxisomal disorders (eg, high forehead, large anterior fontanelle, hypoplastic supraorbital ridges, epicanthal folds, low and broad nasal bridge, high-arched palate, and deformed ear lobes in Zellweger syndrome) (",
"      <a class=\"graphic graphic_picture graphicRef72662 \" href=\"UTD.htm?19/62/20454\">",
"       picture 1",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H17#H17\">",
"       \"Peroxisomal disorders\", section on 'Zellweger syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lysosomal storage diseases (eg, coarse facial features may be present at birth in mucolipidosis II and GM1-gangliosidosis; in other mucopolysaccharidoses coarsening of the facial features develops with age) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Homocystinuria due to cystathionine-beta-synthetase deficiency (long face and lanky body habitus [Marfanoid phenotype])",
"     </li>",
"     <li>",
"      Smith-Lemli-Opitz syndrome (cleft palate, congenital heart disease, hypospadias, polydactyly, and syndactyly)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ophthalmologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmologic presentations of IEM include cataracts, corneal opacities or clouding (",
"    <a class=\"graphic graphic_picture graphicRef52924 \" href=\"UTD.htm?15/2/15392\">",
"     picture 2",
"    </a>",
"    ), cherry red spots (",
"    <a class=\"graphic graphic_picture graphicRef65650 \" href=\"UTD.htm?19/14/19680\">",
"     picture 3",
"    </a>",
"    ), retinitis pigmentosa (",
"    <a class=\"graphic graphic_picture graphicRef81281 \" href=\"UTD.htm?43/24/44418\">",
"     picture 4",
"    </a>",
"    ), and dislocated lenses (",
"    <a class=\"graphic graphic_table graphicRef64851 \" href=\"UTD.htm?29/17/29980\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=see_link\">",
"     \"Ectopia lentis (dislocated lens) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=see_link\">",
"     \"Retinitis pigmentosa: Clinical presentation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Dermatologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermatologic manifestations of IEM may include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rashes &mdash; Acrodermatitis enteropathica (",
"      <a class=\"graphic graphic_picture graphicRef71329 \" href=\"UTD.htm?39/34/40481\">",
"       picture 5",
"      </a>",
"      ), biotinidase deficiency, methylmalonic acidemia, propionic acidemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Photosensitivity &mdash; Porphyrias, Hartnup disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"       \"Porphyrias: An overview\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperkeratosis and ichthyosis (",
"      <a class=\"graphic graphic_picture graphicRef66723 \" href=\"UTD.htm?8/8/8322\">",
"       picture 6",
"      </a>",
"      ) &mdash; Tyrosinemia type II, Sj&ouml;gren-Larsson syndrome, steroid sulfatase deficiency, multiple sulfatase deficiency, congenital disorders of glycosylation, Refsum disease (adult form) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link&amp;anchor=H12#H12\">",
"       \"Disorders of tyrosine metabolism\", section on 'Hereditary tyrosinemia type 2'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35671?source=see_link\">",
"       \"Sj&ouml;gren-Larsson syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=see_link&amp;anchor=H40#H40\">",
"       \"Peroxisomal disorders\", section on 'Refsum disease'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Skin ulceration &mdash; Prolidase deficiency",
"     </li>",
"     <li>",
"      Skin nodules &mdash; Farber disease, congenital disorder of glycosylation",
"     </li>",
"     <li>",
"      Angiokeratoma (",
"      <a class=\"graphic graphic_picture graphicRef81624 graphicRef71039 \" href=\"UTD.htm?18/36/19016\">",
"       picture 7A-B",
"      </a>",
"      ) &mdash; Fabry disease and other lysosomal storage diseases (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=see_link\">",
"       \"Clinical features and diagnosis of Fabry disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pearly papules &mdash; Mucopolysaccharidosis II (Hunter syndrome) (",
"      <a class=\"graphic graphic_picture graphicRef65695 \" href=\"UTD.htm?5/41/5791\">",
"       picture 8",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Hypopigmentation &mdash; Untreated phenylketonuria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=see_link\">",
"       \"Overview of phenylketonuria\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hydrops fetalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonimmune hydrops fetalis (abnormal fetal fluid collections) may occur in the following IEM (",
"    <a class=\"graphic graphic_table graphicRef57407 \" href=\"UTD.htm?24/50/25387\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/22-24\">",
"     22-24",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link\">",
"     \"Nonimmune hydrops fetalis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lysosomal storage diseases, including, but not limited to Gaucher disease, mucopolysaccharidosis types IV and VII, GM1 gangliosidosis, Niemann-Pick Disease type C, Farber disease, infantile free sialic acid storage disease, sialidosis, galactosialidosis, mucolipidosis type II (I cell disease) (see appropriate topic reviews)",
"     </li>",
"     <li>",
"      Neonatal hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/25\">",
"       25",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=see_link&amp;anchor=H23#H23\">",
"       \"Causes of neonatal cholestasis\", section on 'Gestational alloimmune liver disease (neonatal hemochromatosis)'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mitochondrial respiratory chain disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/26\">",
"       26",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=see_link\">",
"       \"Mitochondrial myopathies: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital disorders of glycosylation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/28\">",
"       28",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42564?source=see_link\">",
"       \"Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Red blood cell (RBC) enzyme abnormalities (glucose-6-phosphate dehydrogenase deficiency, pyruvate kinase deficiency, and glucose phosphate isomerase deficiency) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"       \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=see_link\">",
"       \"Pyruvate kinase deficiency\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2366118\">",
"    <span class=\"h2\">",
"     Abnormal odors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal odor of the patient's breath, urine (",
"    <a class=\"graphic graphic_table graphicRef74441 \" href=\"UTD.htm?20/58/21420\">",
"     table 10",
"    </a>",
"    ), perspiration, saliva, or cerumen should prompt consideration of organic acidemias, amino acid disorders, urea cycle defects, and fatty acid oxidation disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/6,16,29\">",
"     6,16,29",
"    </a>",
"    ]. However, the majority of patients who have an unusual odor do not have an IEM or other underlying medical cause for the odor.",
"   </p>",
"   <p>",
"    Odors characteristic of selected disorders are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/3,6,16,29\">",
"     3,6,16,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Burnt sugar, curry, or maple syrup &mdash; Maple syrup urine disease (note: fenugreek, a spice commonly used in Asian cooking, artificial maple syrup, and herbal teas contains sotolon, which can result in a maple syrup smell when consumed)",
"     </li>",
"     <li>",
"      Sweaty socks or cheese-like &mdash; Isovaleric acidemia",
"     </li>",
"     <li>",
"      Fruity, ammoniacal &mdash; Methylmalonic acidemia or propionic acidemia",
"     </li>",
"     <li>",
"      Mouse urine, musty &mdash; Phenylketonuria",
"     </li>",
"     <li>",
"      Cabbage-like, rotten eggs &mdash; Tyrosinemia",
"     </li>",
"     <li>",
"      Malt or hops &mdash; Methionine malabsorption",
"     </li>",
"     <li>",
"      Cat urine &mdash; 3-Methylcrotonic acidemia, 3-hydroxy-3-methylglutaric aciduria",
"     </li>",
"     <li>",
"      Fish-like &mdash; Trimethylaminuria and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      excess",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Urine changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal urine color or odor may be suggestive of IEM (",
"    <a class=\"graphic graphic_table graphicRef74441 \" href=\"UTD.htm?20/58/21420\">",
"     table 10",
"    </a>",
"    ). Color changes may only be apparent after the urine stands for some time (permitting oxidation). This is particularly true for alkaptonuria, and in the era of flush toilets and disposable diapers, explains why the diagnosis is rarely made until later in life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link&amp;anchor=H19#H19\">",
"     \"Disorders of tyrosine metabolism\", section on 'Alkaptonuria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11382266\">",
"    <span class=\"h1\">",
"     AGE AT PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial symptoms of metabolic diseases may occur in any age group, from fetuses and newborns to people in their seventh decade of life. The onset and severity may be influenced by changes in dietary intake, fasting, dehydration, intercurrent illness, medications, strenuous activity, childbirth, trauma, or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/1\">",
"     1",
"    </a>",
"    ]. The presenting signs and symptoms of some disorders may vary with age.",
"   </p>",
"   <p>",
"    As an example, the typical presentation of urea cycle disorders or organic acidemias in newborns is an acute, severe illness characterized by lethargy, poor feeding, vomiting, and shock. However, less severe forms of these disorders may present in older children or adults with episodes of vomiting and lethargy, failure to thrive, protein intolerance, seizures, or psychomotor abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=see_link\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"     \"Organic acidemias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In neonates, the age at the time of presentation may be helpful in narrowing down the specific category of IEM, although there are exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonketotic hyperglycinemia, urea cycle disorders, and branched-chain organic acidemias often present with life-threatening illness between 12 and 72 hours of age, whereas maple syrup urine disease usually presents later in the first week. However, mild forms of all IEM exist and many patients may have the first metabolic decompensation anywhere from 1 to 60 years of age. Parturition is an especially dangerous time for women with undiagnosed IEM. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In neonates with acute liver failure, neonatal hemochromatosis usually presents during the first week, galactosemia in the first or second week, tyrosinemia type 1 any time after the first week, and alpha-1 antitrypsin deficiency, Niemann-Pick disease, and bile acid synthesis defects after the third week. Mitochondrial disorders may present at any time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=see_link&amp;anchor=H18338361#H18338361\">",
"       \"Acute liver failure in children: Etiology and evaluation\", section on 'Inherited metabolic disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of an IEM should be considered in infants, children, and adults who present with otherwise unexplained acid-base disorders, hyperammonemia, hypoglycemia, hematologic abnormalities, liver dysfunction, and renal disease. In some disorders, the laboratory abnormalities may be present only during an acute presentation. Thus, for example, a normal plasma ammonia level in an individual who is not acutely ill does",
"    <strong>",
"     not",
"    </strong>",
"    rule out a metabolic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14590188\">",
"    <span class=\"h2\">",
"     Acid-base disorders, hyperammonemia, and hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid-base disorders, hyperammonemia, and hypoglycemia associated with IEM are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3681940#H3681940\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Laboratory findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Hematologic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic manifestations of IEM may involve any or all of the cell lines, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macrocytic anemia &mdash; Homocystinuria, methylmalonic acidemia, orotic aciduria, lysinuric protein intolerance (a disorder of amino acid transport), Lesch-Nyhan syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=see_link&amp;anchor=H25#H25\">",
"       \"Hyperkinetic movement disorders in children\", section on 'Lesch-Nyhan syndrome'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Normocytic anemia &mdash; Neonatal hemochromatosis, disorders associated with severe liver failure, Wilson disease, porphyria, Wolman disease, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, orotic aciduria, erythropoietic glycolytic enzyme deficiency (eg, pyruvate kinase, phosphofructokinase, glucose-6-phosphate dehydrogenase) (see appropriate topic reviews).",
"     </li>",
"     <li>",
"      Predominant or isolated neutropenia &mdash; Glycogen storage disease type Ib, lysinuric protein intolerance, congenital orotic aciduria, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, mevalonic aciduria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link\">",
"       \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Predominant thrombocytopenia &mdash; Cobalamin metabolism defect (Cbl C), methylmalonic acidemia, propionic acidemia, isovaleric acidemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pancytopenia &mdash; Gaucher disease, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, mevalonic aciduria, lysinuric protein intolerance (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=see_link\">",
"       \"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link\">",
"       \"Organic acidemias\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Liver abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;IEM may be associated with hyperammonemia and jaundice. In addition, IEM that are associated with liver failure also may result in bleeding diathesis (eg, tyrosinemia type 1, glutaric aciduria type I). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3682097#H3682097\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Hyperammonemia'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H20\">",
"     'Jaundice'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link\">",
"     \"Disorders of tyrosine metabolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=see_link&amp;anchor=H33#H33\">",
"     \"Organic acidemias\", section on 'Glutaric aciduria type 1'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease accompanies several IEM. The spectrum of renal disease may include [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24489/abstract/3,15\">",
"     3,15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal Fanconi syndrome &mdash; Tyrosinemia type I, cystinosis, mitochondrial respiratory chain disorders",
"     </li>",
"     <li>",
"      Renal tubular acidosis &mdash; Pyruvate carboxylase deficiency, methylmalonic aciduria,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      palmitoyl transferase I deficiency (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=see_link\">",
"       \"Overview of renal tubular acidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nephrolithiasis &mdash; Cystinuria, gout and other purine disorders, hyperoxaluria, hereditary renal hypouricemia, Lesch-Nyhan syndrome",
"     </li>",
"     <li>",
"      Renal cysts &mdash; Multiple acyl-CoA dehydrogenase deficiency (glutaric acidemia type II), neonatal",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"       carnitine",
"      </a>",
"      palmitoyltransferase type II (CPT II) deficiency, peroxisomal disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital metabolic diseases (",
"      <a class=\"graphic graphic_table graphicRef82924 \" href=\"UTD.htm?39/44/40651\">",
"       table 1",
"      </a>",
"      ) can present in newborns, infants, children, or adults. The onset and severity may be influenced by changes in dietary intake, fasting, dehydration, intercurrent illness, medications, strenuous activity, childbirth, trauma, or surgery. The signs and symptoms vary depending upon the age and disorder. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individual IEM are rare disorders, most having an incidence of less than 1 per 100,000 births. However, the collective incidence may approach 1 in 800 to 2500 births. (See",
"      <a class=\"local\" href=\"#H3709423\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most metabolic disorders are caused by a single enzyme deficiency that disrupts one step of a metabolic pathway. Less frequently, alterations that result in abnormalities of more than one enzyme can affect several metabolic steps. Disorders of cofactors also can affect multiple enzymes. (See",
"      <a class=\"local\" href=\"#H3709430\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metabolic disorders usually result from single mutations, deletions, or other genetic changes. However, a single enzyme can be composed of multiple subunits encoded by different genes and catalyze more than one metabolic reaction. In addition, defects in different enzymes can result in a similar clinical phenotype. (See",
"      <a class=\"local\" href=\"#H3709430\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic and gastrointestinal symptoms and signs are the most common presenting features of IEM. Neurologic features of IEM include lethargy, coma, seizures, developmental delay or regression, peripheral neuropathy, abnormalities of tone, weakness, ataxia, and neuropsychiatric manifestations. Exercise intolerance, muscle pain, or muscle cramps rather than weakness may be the presenting complaint in patients with metabolic myopathies. Gastrointestinal presentations of IEM include recurrent episodes of vomiting, diarrhea, organomegaly, and jaundice. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Neurologic'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Gastrointestinal'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link\">",
"       \"Approach to the metabolic myopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H16728975#H16728975\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Clinical presentations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Laboratory presentations of IEM include acid-base disorders, hyperammonemia, hypoglycemia, anemia, neutropenia, thrombocytopenia, and abnormalities of liver function (eg, hyperbilirubinemia, elevated transaminases, coagulopathy). In some disorders, the laboratory abnormalities may be present only during an acute presentation. Thus, for example, a normal plasma ammonia level in an individual who is not acutely ill does",
"      <strong>",
"       not",
"      </strong>",
"      rule out a metabolic disorder. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link&amp;anchor=H3681940#H3681940\">",
"       \"Inborn errors of metabolism: Metabolic emergencies\", section on 'Laboratory findings'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Weiner DL. Metabolic emergencies. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/2\">",
"      Maestri NE, Clissold D, Brusilow SW. Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis. J Pediatr 1999; 134:268.",
"     </a>",
"    </li>",
"    <li>",
"     Saudubray JM, Chappentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1327.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/4\">",
"      Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatr 2006; 95:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/5\">",
"      Lindor NM, Karnes PS. Initial assessment of infants and children with suspected inborn errors of metabolism. Mayo Clin Proc 1995; 70:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/6\">",
"      Wappner RS. Biochemical diagnosis of genetic diseases. Pediatr Ann 1993; 22:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/7\">",
"      Champion MP. An approach to the diagnosis of inherited metabolic disease. Arch Dis Child Educ Pract Ed 2010; 95:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/8\">",
"      Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000; 105:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/9\">",
"      Sanderson S, Green A, Preece MA, Burton H. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child 2006; 91:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/10\">",
"      Cleary MA, Green A. Developmental delay: when to suspect and how to investigate for an inborn error of metabolism. Arch Dis Child 2005; 90:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/11\">",
"      Curry CJ, Stevenson RE, Aughton D, et al. Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics. Am J Med Genet 1997; 72:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/12\">",
"      Powell K, Van Naarden Braun K, Singh R, et al. Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism. J Pediatr 2010; 156:420.",
"     </a>",
"    </li>",
"    <li>",
"     De Vivo DC, DiMauro S. Hereditary and acquired types of myopathy. In: Oski's pediatrics. Principles and practice, 3rd ed, McMillan JA, DeAngelis CD, Feigin RD, Warshaw JB (Eds), Lippincott, Williams and Wilkins, Philadelphia 1999. p.1971.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/14\">",
"      Scheuerle AE, McVie R, Beaudet AL, Shapira SK. Arginase deficiency presenting as cerebral palsy. Pediatrics 1993; 91:995.",
"     </a>",
"    </li>",
"    <li>",
"     Wappner RS, Hainline BE. Introduction to inborn errors of metabolism. In: Oski's pediatrics. Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.2145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/16\">",
"      Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998; 102:E69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/17\">",
"      Cormier-Daire V, Rustin P, R&ouml;tig A, et al. Craniofacial anomalies and malformations in respiratory chain deficiency. Am J Med Genet 1996; 66:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/18\">",
"      von Kleist-Retzow JC, Cormier-Daire V, Viot G, et al. Antenatal manifestations of mitochondrial respiratory chain deficiency. J Pediatr 2003; 143:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/19\">",
"      Poll-The BT, Maillette de Buy Wenniger-Prick CJ. The eye in metabolic diseases: clues to diagnosis. Eur J Paediatr Neurol 2011; 15:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/20\">",
"      Demitsu T, Kakurai M, Okubo Y, et al. Skin eruption as the presenting sign of Hunter syndrome IIB. Clin Exp Dermatol 1999; 24:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/21\">",
"      Prystowsky SD, Maumenee IH, Freeman RG, et al. A cutaneous marker in the Hunter syndrome a report of four cases. Arch Dermatol 1977; 113:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/22\">",
"      Van Maldergem L, Jauniaux E, Fourneau C, Gillerot Y. Genetic causes of hydrops fetalis. Pediatrics 1992; 89:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/23\">",
"      Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr 1999; 46:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/24\">",
"      Kattner E, Sch&auml;fer A, Harzer K. Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease. Eur J Pediatr 1997; 156:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/25\">",
"      Wisser J, Schreiner M, Diem H, Roithmeier A. Neonatal hemochromatosis: a rare cause of nonimmune hydrops fetalis and fetal anemia. Fetal Diagn Ther 1993; 8:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/26\">",
"      Fayon M, Lamireau T, Bioulac-Sage P, et al. Fatal neonatal liver failure and mitochondrial cytopathy: an observation with antenatal ascites. Gastroenterology 1992; 103:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/27\">",
"      de Koning TJ, Toet M, Dorland L, et al. Recurrent nonimmune hydrops fetalis associated with carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis 1998; 21:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/28\">",
"      Alegria A, Martins E, Dias M, et al. Glycogen storage disease type IV presenting as hydrops fetalis. J Inherit Metab Dis 1999; 22:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24489/abstract/29\">",
"      Mace JW, Goodman SI, Centerwall WR, Chinnock RF. The child with an unusual odor. A clinical resum&eacute;. Clin Pediatr (Phila) 1976; 15:57.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2936 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24489=[""].join("\n");
var outline_f23_58_24489=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3709423\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3709430\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Neurologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14590174\">",
"      - Lethargy, coma, and seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Developmental delay",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Abnormal tone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ataxia and dystonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Neuropsychiatric",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14590181\">",
"      - Vomiting and poor feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Organomegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Jaundice",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Dysmorphic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ophthalmologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Dermatologic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2366118\">",
"      Abnormal odors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Urine changes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11382266\">",
"      AGE AT PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14590188\">",
"      Acid-base disorders, hyperammonemia, and hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Hematologic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Liver abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2936\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2936|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?6/26/6575\" title=\"algorithm 1\">",
"      Urea cycle disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2936|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/62/20454\" title=\"picture 1\">",
"      Zellweger syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/2/15392\" title=\"picture 2\">",
"      Corneal clouding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/14/19680\" title=\"picture 3\">",
"      Cherry red spot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/24/44418\" title=\"picture 4\">",
"      Ocular fundus in pt with RP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/34/40481\" title=\"picture 5\">",
"      Acrodermatitis enteropathica",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/8/8322\" title=\"picture 6\">",
"      X-linked ichthyosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/29/38353\" title=\"picture 7A\">",
"      Angiokeratomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/11/33972\" title=\"picture 7B\">",
"      Elevated papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/41/5791\" title=\"picture 8\">",
"      Hunter syndrome papular rash",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2936|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/44/40651\" title=\"table 1\">",
"      Types of inborn errors of metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/23/8572\" title=\"table 2\">",
"      Disorders of carbohydrate metab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/13/8411\" title=\"table 3\">",
"      Mitochondrial disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/62/22507\" title=\"table 4\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/60/8140\" title=\"table 5\">",
"      Selected lysosomal storage disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/12/24780\" title=\"table 6\">",
"      Disorders of fatty acid oxidation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/36/26187\" title=\"table 7\">",
"      Classification organic acidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/17/29980\" title=\"table 8\">",
"      Ophth findings IEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/50/25387\" title=\"table 9\">",
"      Metabolic causes hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/58/21420\" title=\"table 10\">",
"      Urinary clues to inborn errors of metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/55/22394?source=related_link\">",
"      Acute liver failure in children: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34004?source=related_link\">",
"      Approach to the infant with hypotonia and weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/50/16169?source=related_link\">",
"      Causes of neonatal cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/970?source=related_link\">",
"      Classification and evaluation of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40137?source=related_link\">",
"      Clinical features and diagnosis of Fabry disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30886?source=related_link\">",
"      Clinical features and diagnosis of galactosemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=related_link\">",
"      Ectopia lentis (dislocated lens) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16010?source=related_link\">",
"      Etiology of hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9402?source=related_link\">",
"      Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=related_link\">",
"      Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42564?source=related_link\">",
"      Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/34/13861?source=related_link\">",
"      Glycogen debrancher deficiency (glycogen storage disease III)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/40/18058?source=related_link\">",
"      Hyperkinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27047?source=related_link\">",
"      Inborn errors of metabolism: Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13177?source=related_link\">",
"      Inborn errors of metabolism: Identifying the specific disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5257?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/12/7370?source=related_link\">",
"      Mitochondrial myopathies: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7914?source=related_link\">",
"      Organic acidemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33098?source=related_link\">",
"      Overview of acquired peripheral neuropathies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/58/35753?source=related_link\">",
"      Overview of phenylketonuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10759?source=related_link\">",
"      Overview of renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8570?source=related_link\">",
"      Peroxisomal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27559?source=related_link\">",
"      Pyruvate kinase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=related_link\">",
"      Retinitis pigmentosa: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35671?source=related_link\">",
"      Sj&ouml;gren-Larsson syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_58_24490="Diseases of the chest wall";
var content_f23_58_24490=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diseases of the chest wall",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24490/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24490/contributors\">",
"     Richard M Schwartzstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24490/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24490/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/58/24490/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/58/24490/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/58/24490/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest wall is a critical component of the respiratory pump. Diseases that alter the structure of the chest wall affect the function of the pump, and may result in respiratory compromise or failure. The components of the chest wall include the bony structures (ribs, spine), respiratory muscles, and nerves connecting the central nervous system with the respiratory muscles.",
"   </p>",
"   <p>",
"    Chest wall structure and physiology and diseases that affect the bony portion of the chest wall will be reviewed here. Included are discussions of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ankylosing spondylitis",
"     </li>",
"     <li>",
"      Congenital deformities, including pectus excavatum",
"     </li>",
"     <li>",
"      Flail chest",
"     </li>",
"     <li>",
"      Kyphoscoliosis",
"     </li>",
"     <li>",
"      Thoracoplasty",
"     </li>",
"     <li>",
"      Fibrothorax",
"     </li>",
"     <li>",
"      Abdominal processes, including morbid obesity and ascites",
"     </li>",
"     <li>",
"      Chest wall tumors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various forces acting upon the mechanical structure of the chest wall play a major role in determining lung volume, and chest wall abnormalities can have a significant impact on lung function. Abnormalities of the bony structures of the chest wall and abdominal processes that affect respiration will be reviewed here. Diseases affecting chest wall nerves and muscles are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3528?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=see_link\">",
"     \"Respiratory physiologic changes following spinal cord injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL STRUCTURE AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rib cage and vertebral column form the boundaries of the chest wall superiorly and laterally, while the diaphragm constitutes the inferior component. Changes in the intra-abdominal contents or compliance of the abdominal wall alter the mechanical properties of the chest wall through their effects on the motion of the diaphragm. The external boundary of the lower chest wall is the lower border of the rib cage, but internally, this boundary overlaps with the diaphragm, which covers as much as one-half of the rib cage at residual volume (RV). By virtue of this \"zone of apposition\" between the diaphragm and the ribs, the rib cage is exposed both to abdominal and pleural pressures, such that the normal function of the chest wall depends on the intricate interaction of the two spaces.",
"   </p>",
"   <p>",
"    The mechanics of the chest wall are described by a pressure-volume curve, which differs in the upright and supine positions because the abdominal contents are displaced into the thoracic cavity when supine (",
"    <a class=\"graphic graphic_figure graphicRef81887 \" href=\"UTD.htm?25/55/26494\">",
"     figure 1",
"    </a>",
"    ). In the upright position, the resting volume of the chest wall is approximately 75 percent of vital capacity (VC). The rib cage recoils outward when the volume is smaller and recoils inward when the volume is larger. In contrast, the resting volume of the respiratory system as a whole &ndash; the functional residual capacity (FRC) &ndash; is approximately 35 percent of VC. This measure takes into account the mechanical properties of the chest wall plus the inward recoil of the lung.",
"   </p>",
"   <p>",
"    The intragastric pressure (Pga) is an estimate of the intraabdominal pressure. The difference between Pga and pleural pressure (Ppl) is the transdiaphragmatic pressure (Pdi). In other words, Pga - Ppl = Pdi. Above FRC at a relaxed position, Pdi is zero, with no passive diaphragmatic stretch. Below FRC, Pga exceeds Ppl, and Pdi is positive, reflecting passive stretch of the diaphragm. Below this volume (functional residual capacity [FRC]), Pga exceeds Ppl, and Pdi is positive, reflecting passive stretch of the diaphragm. In the supine position, gravity pulls the abdominal contents into the thoracic cavity (the \"expiratory effect\"), and the resting volumes are less than when erect by 15 percent of the vital capacity. At any given lung volume in this position, Pga is more positive, and the diaphragm is stretched at resting volumes. In the lateral position, the \"expiratory effect\" applies to the dependent side, such that the vital capacities may differ by 20 percent between the two lungs. As a general rule, the greater the stretch of the diaphragm (ie, the longer the muscle at the time it receives a neurologic stimulus), the greater the tension generated in the muscle. When Pga is high, however, the ability to inspire is hampered by the impedance of the abdominal cavity.",
"   </p>",
"   <p>",
"    The excursion of the chest wall depends upon complex interactions between its components. The motion of the ribs depends upon their attachments to the sternum and vertebral column and is influenced by the adjoining muscle groups. The parasternal and scalene muscles insert on ribs 1 through 6; the costal portion of the diaphragm inserts on the sternum and ribs 7 through 12. Flexion and extension of the spine can result in displacement of the rib cage and abdominal wall to account for as much as 50 percent of vital capacity. The diaphragm is innervated by the phrenic nerve, traverses an average of 9.5 centimeters during generation of the vital capacity, and affects the rib cage through changes in abdominal and pleural pressures as well as through direct effects upon the ribs on which it inserts. The muscles of the abdominal wall are important muscles of expiration, and contraction of these muscles can also have a significant effect on lung volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANKYLOSING SPONDYLITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankylosing spondylitis is a chronic inflammatory disease affecting joints of the axial skeleton with resultant fibrosis and ossification of the ligamentous structures of the spine, sacroiliac joints, and rib cage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients present most frequently with chronic low back pain, and clinical findings often include limited spinal range of motion, bilateral sacroiliitis on plain radiographs, and positive serology for HLA-B27 in 90 to 95 percent of patients. Individuals may rarely complain of exercise intolerance. Extraarticular manifestations of the illness include ocular disease (anterior uveitis, 25 percent) and cardiovascular disease (including aortitis, aortic insufficiency, aortic root dilation, thoracic aortic aneurysms, conduction abnormalities), and peripheral arthritis occurs in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ankylosing spondylitis causes pleuropulmonary disease in less than 2 percent of patients, most commonly in the form of chest wall restriction and upper lobe fibrocystic parenchymal disease. In a small series of 20 patients with ankylosing spondylitis who were receiving treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , 20 percent of the patients had asymptomatic interstitial lung disease detected by high resolution CT scanning, compared to 2 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/3\">",
"     3",
"    </a>",
"    ]. Less commonly, ankylosing spondylitis affects the cricoarytenoid joint, and patients can present with hoarseness, sore throat, upper airway obstruction, or respiratory failure. In addition, these patients are at increased risk for spinal cord injury when undergoing endotracheal intubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ankylosing spondylitis causes fixation of the chest wall through fusion of the costovertebral joints from inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Similarly, the anterior chest wall can be affected by enthesitis (inflammation of the muscular or tendinous attachments to bone) of the manubriosternal symphysis and sternoclavicular joints. Clinical evidence of chest wall disease includes limitation of chest wall expansion to 2.5 centimeters when measured at the level of the fourth intercostal space [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite chest wall restriction, patients will often manifest only a mild restrictive ventilatory defect, with a mild decrease in the total lung capacity (TLC) and vital capacity (VC) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/4\">",
"     4",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef67150 \" href=\"UTD.htm?21/47/22270\">",
"     figure 2",
"    </a>",
"    ). Relative preservation of lung volumes has been attributed to compensation by the diaphragm with increased abdominal excursion, fixation of the thorax at greater lung volumes, and preservation of chest wall symmetry and rib excursion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/4-6,8\">",
"     4-6,8",
"    </a>",
"    ]. The functional residual capacity (FRC) and residual volume (RV) are normal or increased due to fixation of the rib cage in an inspiratory position. Gas exchange, airflow, and lung compliance are usually normal. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) may be mildly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Exercise tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may rarely complain of exercise intolerance. Formal testing may reveal exercise limitation with decreased maximal oxygen consumption (VO",
"    <sub>",
"     2",
"    </sub>",
"    max), but the extent to which this correlates with limited chest wall expansion is debated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Some authors report that exercise limitation does not occur until the vital capacity (VC) is less than 75 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/12\">",
"     12",
"    </a>",
"    ], while others have invoked additional factors such as deconditioning and inspiratory muscle fatigue to account for the exercise limitation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/13\">",
"     13",
"    </a>",
"    ]. Non-specific body fatigue can confound interpretation of self-reported exercise capacity capability [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is primarily preventive and supportive. There is debate about whether disease activity, as assessed by the erythrocyte sedimentation rate (ESR), correlates with the decline in VC [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. Anti-inflammatory therapy has not been shown to influence the pulmonary disease or the underlying illness. Spinal extension exercises may be beneficial in maintaining mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/6\">",
"     6",
"    </a>",
"    ]. A number of preliminary reports on the use of TNF blockers in ankylosing spondylitis suggest short-term improvement in disease activity ratings and quality of life measures [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Changes in pulmonary function tests and respiratory symptoms have not been assessed consistently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Parenchymal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apical fibrobullous disease develops in approximately 1 percent of patients, with a male to female predominance of 50:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Affected patients have usually suffered from ankylosing spondylitis for at least 15 years. Possible etiologies of this complication include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammatory lung disease",
"     </li>",
"     <li>",
"      Repeated aspiration from associated esophageal muscle dysfunction (with diminished clearance of secretions due to chest wall disease)",
"     </li>",
"     <li>",
"      Decreased ventilation of, or altered apical stresses to, the upper lung fields as a result of chest wall disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The course of the fibrosis may be progressive, and no therapy of uncomplicated apical fibrosis has been shown to alter the direction of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. This condition is usually clinically silent until superinfection occurs, most commonly with Aspergillus or mycobacterial species [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/2\">",
"     2",
"    </a>",
"    ]. Because of the location of pulmonary disease and its radiographic appearance, tuberculosis must be excluded. These patients are also at increased risk for spontaneous pneumothorax. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=see_link\">",
"     \"Secondary spontaneous pneumothorax in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CONGENITAL DEFORMITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several congenital abnormalities can impair chest wall function; of these, pectus excavatum, pectus carinatum, and Poland's syndrome are the most important [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pectus excavatum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pectus excavatum (also called funnel chest) is the most frequent anterior chest wall deformity and is characterized by a concave depression that may be a broad shallow defect or a narrow central pocket (",
"    <a class=\"graphic graphic_picture graphicRef69804 \" href=\"UTD.htm?30/62/31712\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82696 \" href=\"UTD.htm?28/8/28800\">",
"     image 1",
"    </a>",
"    ). The condition affects boys more frequently than girls and usually is discovered within the first year of life. Infants and young children generally have no symptoms, but older patients may complain of mild dyspnea on exertion and pain in the area of rib deformity after exercise. Abnormalities on pulmonary function testing are two to three times less common than subjective pulmonary complaints, and the correlation between the two is poor. However, normal pulmonary function tests do not exclude the possibility of cardiopulmonary limitation during exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18071?source=see_link\">",
"     \"Pectus excavatum: Etiology and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=see_link\">",
"     \"Pectus excavatum: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pectus carinatum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pectus carinatum (also called pigeon chest) is less common than pectus excavatum by a ratio of 1:5 and usually presents with a protrusion of the sternum and costal cartilages. In contrast to pectus excavatum, pectus carinatum often is not discovered until the pubertal growth spurt, and patients often present in adolescence. As with pectus excavatum, the cause is unknown, boys are more frequently affected, and associated conditions include scoliosis and congenital heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=see_link\">",
"     \"Pectus carinatum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Poland syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poland syndrome (also known as Poland sequence) occurs in",
"    <span class=\"nowrap\">",
"     1/30,000",
"    </span>",
"    live births and encompasses a constellation of abnormalities, including aplasia or hypoplasia of breast tissue, nipple, and the sternocostal portion of the pectoralis major muscle, and also absence of the costal cartilages of ribs 2 to 4 or 3 to 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/21\">",
"     21",
"    </a>",
"    ]. Abnormalities of the pectoralis major muscle and hands (syndactyly) are often associated. Repair is undertaken for children with severe chest wall abnormalities, including rib aplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link&amp;anchor=H16#H16\">",
"     \"Breast development and morphology\", section on 'Abnormalities in breast development'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3673?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of breast disorders in children and adolescents\", section on 'Athelia and amastia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Asphyxiating thoracic dystrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asphyxiating thoracic dystrophy (ATD, also called Jeune's syndrome) is an autosomal recessive skeletal dysplasia with multiorgan involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. A defective intraflagellar transport protein caused by mutation of the IFT80 gene has been identified and associated with some cases of ATD [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients generally develop progressive respiratory insufficiency in the first few months of life related to the abnormally small thorax. Cystic kidney disease resulting in renal insufficiency is another common manifestation of ATD; other disease associations include hepatic insufficiency, cystic pancreatic masses, and retinal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]. ATD has been noted in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/26\">",
"     26",
"    </a>",
"    ]; a similar presentation can occur years after pectus excavatum repair surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic options available for ATD include lateral thoracic expansion, dynamic thoracoplasty or sternal and chest wall reconstruction, with or without the use of bone grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FLAIL CHEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant chest wall injury occurs in one-third of patients with severe trauma, and the number of fractured ribs has been shown to correlate with the severity of intrathoracic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Most injury to the chest wall itself occurs through blunt trauma, and the possible injuries include simple rib fractures, sternal fractures, clavicular fractures, and flail chest [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/34\">",
"     34",
"    </a>",
"    ]. Flail chest occurs in 10 to 20 percent of trauma admissions and connotes a mortality as high as 50 percent and perhaps higher in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. The entity is uncommon in children due to a more pliable chest wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flail chest describes an unstable chest wall, usually due to double rib fractures in more than one site (three sequential rib fractures, or fracture of ribs plus sternum). The rib fractures uncouple part of the chest wall from the rib cage, and this segment is therefore subjected to unopposed pleural pressures, resulting in paradoxical motion. The flail segment can be missed early in the clinical course because of muscle splinting, which may conceal motion of the segment. The mechanism of injury is usually direct impact of the steering wheel, or crush injury. A flail segment can occur in different locations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anterior: fracture of the sternum and multiple costochondral junctions",
"     </li>",
"     <li>",
"      Posterior: midaxillary fracture with fracture or dislocation of rib heads",
"     </li>",
"     <li>",
"      Lateral: row of rib fractures both anteriorly and posteriorly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of flail can also be affected by differential recruitment of chest wall muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/36\">",
"     36",
"    </a>",
"    ]. Pulmonary contusion is usually an associated condition and, if present, may account for a significant alveolar-arterial (A-a) gradient. Patients are also at significant risk for pneumonia, atelectasis, and the acute respiratory distress syndrome. Pneumothorax and hemothorax are commonly present and may not develop until later in the course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilation is often ineffective, due to the inability to generate effective intrathoracic pressure. This situation usually results in further atelectasis, which worsens gas exchange. The increased work of breathing and decreased respiratory efficiency place the patient at risk for respiratory muscle fatigue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of flail chest depends in part upon its severity. Conservative management and analgesia may be the only treatment required in minor cases. Active components of treatment include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain control to decrease",
"      <span class=\"nowrap\">",
"       splinting/atelectasis;",
"      </span>",
"      this often requires intercostal nerve blocks or epidural anesthesia.",
"     </li>",
"     <li>",
"      Skeletal splinting with external weights on the flail segment.",
"     </li>",
"     <li>",
"      Internal splinting with positive pressure ventilation. This approach is controversial, since it is not clear that mortality is diminished by mechanical ventilation if intubation is not otherwise required. The suggested mode of ventilation is debated; addition of positive end expiratory pressure (PEEP) may be beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/37-42\">",
"       37-42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgical fixation of the flail region may be indicated for some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/37,43\">",
"       37,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thoracic and shoulder chest physiotherapy may decrease long-term disability from the flail chest deformity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    External splinting to minimize motion of the flail segment is discouraged because it may further reduce ventilation of the underlying lung and predispose the patient to atelectasis, retained secretions, and pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     KYPHOSCOLIOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kyphosis represents anteroposterior angulation of the spine and is a normal finding in most individuals. Scoliosis represents lateral displacement or curvature of the spine. When the angulation of kyphosis is excessive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    moderate to severe scoliosis is present, severe rib distortion may result. Scoliosis is usually associated with increased kyphosis, but kyphosis can occur in isolation.",
"   </p>",
"   <p>",
"    Hyperkyphosis is excessive curvature of the thoracic spine, commonly known as the \"dowager's hump.\" The term kyphosis is meant to describe the sagittal convexity, or forward curvature, of the normal thoracic spine which can range from normal to abnormal, although the term is sometimes used in reference to hyperkyphosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35769?source=see_link\">",
"     \"Overview of hyperkyphosis in older persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of these two conditions is defined by measurement of the Cobb angle of curvature that is formed by the limbs of the convex primary curvature (",
"    <a class=\"graphic graphic_figure graphicRef51638 \" href=\"UTD.htm?3/47/3824\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of kyphoscoliosis are listed in the table and relate to defects in supporting structures of the chest wall (",
"    <a class=\"graphic graphic_table graphicRef57062 \" href=\"UTD.htm?23/3/23611\">",
"     table 1",
"    </a>",
"    ). The most common cause is idiopathic (80 percent) and begins in childhood, while the other causes are secondary to an underlying illness. Diagnosis is made by physical examination, although the extent is often underestimated until radiographs are visualized. The degree of spinal deformity is the most important risk factor for respiratory failure, and the effects of kyphosis and scoliosis are additive in lung function impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/44\">",
"     44",
"    </a>",
"    ]. In patients who exhibit primarily kyphosis, deformity above T10 is associated with a greater degree of respiratory impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;A restrictive pattern of pulmonary function usually is seen, with decreased total lung capacity (TLC) and vital capacity (VC) in proportion to the spinal deformity and preserved residual volume (RV), such that the",
"    <span class=\"nowrap\">",
"     RV/TLC",
"    </span>",
"    ratio is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/44,46-48\">",
"     44,46-48",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef67150 \" href=\"UTD.htm?21/47/22270\">",
"     figure 2",
"    </a>",
"    ). Radiographic assessment of scoliosis predicts only a small amount of the pulmonary function variability in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/49\">",
"     49",
"    </a>",
"    ]; other factors, such as sagittal diameter of the thoracic cage and total lung area, may add to the ability to predict the effect on vital capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/50\">",
"     50",
"    </a>",
"    ]. The reduced compliance of the chest wall changes its resting position, such that functional residual capacity (FRC) is decreased. Lung compliance eventually decreases due to progressive atelectasis and air trapping, a consequence of breathing at low lung volumes. This reduced compliance of the entire respiratory system increases the work of breathing. Interestingly, children with spinal deformities have normal chest wall compliance, perhaps due to their more pliant chest walls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) are decreased (one-half normal in eucapnic patients and one-quarter normal in hypercapnic patients), either due to intrinsic muscle weakness or mechanical disadvantage due to the rib cage distortion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/47,52\">",
"     47,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additionally, chest wall compliance decreases with age, further increasing work of breathing and risk of respiratory muscle fatigue in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Hence, these patients tend to breathe with lower tidal volumes and increased respiratory rate. Although this breathing pattern decreases respiratory effort, dead space fraction may be increased, and alveolar hypoventilation may ensue with resultant hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/44\">",
"     44",
"    </a>",
"    ]. Otherwise, hypoxemia without hypercapnia is seen in moderate to severe disease, and ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatch has been reported with a scoliosis angle greater than 65 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. Pulmonary hypertension develops in some patients as a result of persistent hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/55\">",
"     55",
"    </a>",
"    ]. Nocturnal hypoventilation and arterial oxygen desaturation are described, particularly during rapid eye movement (REM) sleep. This is likely a result of decreased accessory muscle use during REM, as well as possible distortion of the upper airway, which predisposes to apneic events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Exercise tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise limitation is often present in patients with kyphoscoliosis. However, the indices of ventilatory performance during exercise are essentially normal in these patients with the exception of reduced tidal volumes. There is a normal breathing pattern response to exercise and a normal maximum tidal volume to vital capacity ratio. Hence, exercise intolerance may be a result of physical deconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild kyphoscoliosis has a good prognosis and requires supportive care only, while more severe kyphoscoliosis can result in progressive respiratory failure and cor pulmonale [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/44\">",
"     44",
"    </a>",
"    ]. In the presence of established kyphoscoliosis in adults, surgery is of questionable benefit and carries a significant complication rate, although surgery and bracing are used to treat idiopathic scoliosis in selected adolescents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37065?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment and prognosis of adolescent idiopathic scoliosis\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Medical therapy for respiratory dysfunction due to kyphoscoliosis includes pulmonary rehabilitation, which may improve pulmonary function and exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/59\">",
"     59",
"    </a>",
"    ], and noninvasive ventilation. Noninvasive positive pressure ventilation (NPPV) is now preferred over negative pressure ventilation due to ease of application, portability, efficacy, and elimination of obstructive apneas that may be induced by negative pressure ventilators. Patients rarely require tracheostomy for positive pressure ventilation unless there are other comorbidities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=see_link\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Work to date suggests benefit with intermittent nocturnal or longer term use of NPPV, such as improvement in lung volumes, respiratory function, and arterial blood gases. Possible mechanisms of these responses include increases in respiratory system compliance, improved ventilation-perfusion relationships, decreased atelectasis, decreased work of breathing, unloading of the respiratory muscles, and treatment of coexistent sleep-disordered breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/60-69\">",
"     60-69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/6/5222?source=see_link\">",
"     \"The effect of sleep in patients with neuromuscular and chest wall disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=see_link&amp;anchor=H12#H12\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\", section on 'Potential benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective series, NPPV with supplemental oxygen as needed was compared to long-term supplemental oxygen (LTOT) alone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/60\">",
"     60",
"    </a>",
"    ]. NPPV was associated with improved arterial partial pressure of oxygen (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ), arterial partial pressure of carbon dioxide (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ), vital capacity, and a greater one-year survival (100 percent versus 66 percent). In a separate study, 49 patients with kyphoscoliosis had a 75 percent five-year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/70\">",
"     70",
"    </a>",
"    ]. A PaCO",
"    <sub>",
"     2",
"    </sub>",
"    of 50 mmHg or greater one month after initiation of NPPV and comorbid conditions were independent predictors of mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     THORACOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracoplasty represents the resection of ribs or their replacement with an inward convexity device intended to decrease thoracic volume [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/71\">",
"     71",
"    </a>",
"    ]. The only current use of the procedure is closure of a persistent pleural space, but prior to the 1950s, this procedure was performed as collapse therapy for cavitary tuberculosis. The perioperative mortality was high. Survivors had a reasonable life expectancy, though their mortality was still higher than that of control subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracoplasty results in a restrictive ventilatory defect with decreases in TLC and VC and preserved RV (",
"    <a class=\"graphic graphic_figure graphicRef67150 \" href=\"UTD.htm?21/47/22270\">",
"     figure 2",
"    </a>",
"    ). This restrictive defect likely results from diminished volume from chest wall distortion, and perhaps from concomitant pulmonary fibrosis secondary to tuberculosis. The diffusing capacity is usually normal when corrected for alveolar volume.",
"   </p>",
"   <p>",
"    Patients also may have an obstructive ventilatory defect that worsens with age and may be due to either tuberculosis or the effects of cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/72\">",
"     72",
"    </a>",
"    ]. This feature is fairly unique amongst chest wall diseases. Exercise capacity is limited due to diminished ventilatory capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is primarily supportive, with use of noninvasive ventilation in a fashion similar to that for kyphoscoliosis. An associated obstructive ventilatory component, when present, should be treated with bronchodilators. A course of pulmonary rehabilitation may be helpful in improving symptoms and increasing six-minute walk distances for these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     FIBROTHORAX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrothorax results from fibrosis of the visceral pleura surrounding the lung, and is clinically manifested by decreased respiratory excursion and restrictive pulmonary physiology. Although fibrothorax is the result of underlying pleural or pulmonary disease, the physiologic manifestations are similar to those seen in chest wall disorders. There are two distinct mechanisms that can lead to the formation of fibrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most often, fibrothorax develops as a consequence of pleural inflammation in patients with pleural effusions. Common clinical examples include incompletely evacuated hemothorax, tuberculous effusion, or chronic empyema.",
"     </li>",
"     <li>",
"      Less frequently, fibrothorax results from pulmonary parenchymal disease, and can be seen in patients with inadequately treated tuberculosis, bronchiectasis, or lung abscess.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Generally, the symptoms of the primary disease have abated when the effects of the fibrotic process become clinically apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any of the processes noted above can result in pleural scarring and development of fibrous tissue that replaces and obliterates the pleural cavity. In severe cases, particularly those of untreated empyema, the fibrotic process can invade the chest wall, destroy the intercostal structures, replace the endothoracic fascia, and cause thickening of the periosteum of the ribs. Ultimately, the ribs can fuse, and calcification of collagen can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/77\">",
"     77",
"    </a>",
"    ]. This results in a limitation of respiratory excursion, and may lead to the development of scoliosis. The fibrotic process does not traverse the diaphragm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitation in chest wall movement results in a restrictive ventilatory defect on pulmonary function testing, similar to other disease processes that result in decreased chest wall compliance. Fibrothorax can result in a characteristic, abrupt cessation of flow at end-inspiration; however, effort-related cessation of flow may mimic this finding. Hypercarbia from alveolar hypoventilation can develop as a consequence of lung entrapment, and perfusion to the affected hemithorax appears to be reduced out of proportion to the drop in ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since treatment of severe fibrothorax is difficult, the best strategy is to make appropriate interventions in patients with complicated pleural effusions that otherwise might evolve into fibrothorax. For example, early drainage of empyemas and hemothoraces and instillation of fibrinolytic agents into the pleural space of patients with complicated parapneumonic effusions will reduce the risk of fibrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once present, fibrothorax can resolve over time spontaneously in some cases, such as those from hemothorax and tuberculous pleuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/77,81\">",
"     77,81",
"    </a>",
"    ]. In other situations, especially once respiratory insufficiency has ensued, further intervention may be necessary to relieve chest wall restriction. Open surgical decortication is considered definitive therapy, although the degree of improvement depends to a large extent on the condition of the underlying lung. Patients with significant underlying parenchymal lung disease do not gain the same benefit from decortication as do those with normal lung parenchyma. Video-assisted thoracotomy (VATS) sometimes can avert the need for standard thoracotomy in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ABDOMINAL PROCESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described previously, processes that alter intraabdominal pressure can profoundly affect the compliance of the chest wall and pulmonary function. This section will focus on the chest wall effects of simple obesity, uncomplicated by carbon dioxide retention or obstructive sleep apnea (which are discussed elsewhere), and ascites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of obesity is most commonly determined by the body mass index (BMI), which is calculated by dividing the body weight (in kg) by the height (in meters) squared. A BMI greater than 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is commonly used as a definition of obesity (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total lung capacity (TLC) and functional residual capacity (FRC) are both reduced by obesity because the increased mass of the chest wall alters the balance of forces (recoil of chest wall, lungs, and muscle force) that determine these lung volumes. In contrast, residual volume (RV) is relatively preserved in obese individuals older than 40 years because it is largely determined by dynamic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/83\">",
"     83",
"    </a>",
"    ]. Specifically, elastic recoil of the lung decreases, airways increasingly narrow at low lung volumes and airway resistance becomes a determining factor for RV.",
"   </p>",
"   <p>",
"    Some authors have reported a normal vital capacity (VC) until the extremes of obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/84\">",
"     84",
"    </a>",
"    ], while others have proposed a decrement across a range of weights, with some suggesting a more specific correlation, such as a loss of 26 cc of VC for each kg gain in weight [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/85\">",
"     85",
"    </a>",
"    ]. Airway resistance is increased in obese patients, presumably due to the increase in pleural pressure that results from the weight of the chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/83\">",
"     83",
"    </a>",
"    ]. When airway resistance is corrected for lung volume, the difference between control and obese subjects is mitigated. Obese individuals tend to breathe at lower lung volumes than non-obese subjects and the diameter of airways is dependent on the absolute volume of the lungs. The forced expiratory volume in one second (FEV1) and the forced vital capacity (FVC) are reduced in obesity both in absolute terms and as a percentage of predicted values [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/83\">",
"     83",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     FEV1/FVC",
"    </span>",
"    ratio is preserved.",
"   </p>",
"   <p>",
"    In severely overweight individuals (mean BMI 44",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    expiratory flow limitation and intrinsic positive end-expiratory pressure (ie, auto-PEEP) may be detected during tidal breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/86\">",
"     86",
"    </a>",
"    ]. These findings are worsened in the supine position. The presence of auto-PEEP further increases the work of breathing, which is already elevated due to reduced compliance of the chest wall and increased airway resistance.",
"   </p>",
"   <p>",
"    Normoxia or mild hypoxemia is usually present in the upright position, though many obese patients develop further hypoxemia as well as expiratory flow limitation when supine [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Gas exchange abnormalities may be the result of",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch with preserved perfusion to the bases and diminished ventilation to those areas from atelectasis. Most patients with simple obesity remain eucapnic despite a large ventilatory demand. These patients generally have an elevated resting respiratory rate with a tidal volume that is normal overall, but is reduced when adjusted for lean body mass [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/89\">",
"     89",
"    </a>",
"    ]. Diffusing capacity is typically greater than normal, when corrected for alveolar volume.",
"   </p>",
"   <p>",
"    Chest wall compliance is mildly reduced, likely from the added pressure of an enlarged abdominal cavity. Lung compliance is reduced by approximately 25 percent, perhaps from increased pulmonary blood volume and early airways closure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/90\">",
"     90",
"    </a>",
"    ]. Respiratory muscle strength is generally preserved, although respiratory muscle efficiency is decreased as a result of increased mechanical work and oxygen cost of breathing. Small decrements in maximal expiratory pressure have been observed and attributed to less effective abdominal muscle contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The changes in lung function noted above may be more severe when the patient moves from the upright to the supine posture [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/83,91\">",
"     83,91",
"    </a>",
"    ]. Patients with severe obesity can develop significant dyspnea in the supine position and often will sleep in a chair to minimize the effect of the abdomen on the compliance of the chest wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Exercise tolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise capacity is frequently reduced due to increased work required to overcome the excess ventilatory load and concomitant cardiovascular deconditioning. Maximal voluntary ventilation (MVV) may be reduced as well [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/84,92\">",
"     84,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest weight loss (some authors report in the range of 35 kg) may improve pulmonary function and exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/93-96\">",
"     93-96",
"    </a>",
"    ]. Proportional assist ventilation, which adjusts the inspiratory pressure in proportion to patient effort, has been shown to increase exercise duration in obese individuals by more than 20 percent in approximately half of subjects tested [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=see_link&amp;anchor=H4#H4\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\", section on 'Ventilators'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Ascites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ascites refers to the accumulation of extravascular fluid within the peritoneum, occurring as a result of a variety of processes, including hypoalbuminemia, heart failure, cirrhosis, and malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=see_link\">",
"     \"Pathogenesis of ascites in patients with cirrhosis\"",
"    </a>",
"    .) Patients often experience shortness of breath once sufficient abdominal fluid has accumulated (usually described as tense ascites), likely as a result of increased intrapleural pressure from abdominal distention. Rigidity of the diaphragm and the thoracic and abdominal walls may affect pulmonary function and increase the work of breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/98\">",
"     98",
"    </a>",
"    ]. Most studies of respiratory function in ascites have been performed in patients with alcoholic cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volumes are generally reduced, with mild to moderate reductions in FRC, TLC, FVC, and ERV reported by multiple authors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/98-102\">",
"     98-102",
"    </a>",
"    ]. Mild to moderate improvement in lung volumes, most consistently in the FRC and TLC, are seen after large-volume paracentesis. The DLCO, FEV1, and PaO",
"    <sub>",
"     2",
"    </sub>",
"    are usually reduced but may not improve after paracentesis. In contrast, lung volumes may be preserved in pregnancy, another condition associated with increased intra-abdominal pressure, due to a \"coupling\" mechanism of the diaphragm and rib cage. It is possible that increased intrapleural pressures prevent such a mechanism in ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ascites may result in an increased elastic load on the lung, as well as positive end-expiratory alveolar pressure (PEEP), possibly due to early airways closure as a consequence of increased intrapleural pressure. These processes result in an increased inspiratory muscle load and work of breathing, which are improved after large volume paracentesis. Inspiratory muscle strength may be normal or mildly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, large volume paracentesis may have a beneficial effect upon lung function. Diuretics are also standard components of treatment in ascites and, based upon one report of 26 patients with non-alcoholic cirrhosis, may have a similar benefit for lung function but a more favorable effect on PaO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=see_link\">",
"     \"Abdominal compartment syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     CHEST WALL TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large tumors of the chest wall can result in pulmonary restriction. The same is true of large masses within the pleural space, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31382?source=see_link\">",
"     \"Imaging of pleural plaques, thickening, and tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Benign neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondroma accounts for 30 to 50 percent of benign bony lesions and presents as a painless mass on the external surface of the rib metaphysis. Young males are most commonly affected. Radiographs usually reveal a pedunculated or sessile mass on the rib surface, with the medulla of the lesion contiguous with the bone medulla. Malignant degeneration to osteochondrosarcoma occurs in less than 1 percent of patients.",
"   </p>",
"   <p>",
"    Fibrous dysplasia accounts for 20 to 30 percent of benign rib tumors and can present as a painful rib lesion or with a pathologic fracture. Radiographically, these lesions are usually lytic and located on the posterior aspect of the rib. Excision is recommended to reduce symptoms or for diagnosis; malignant transformation is rare. Young individuals are affected, and the lesions usually stop growing during puberty.",
"   </p>",
"   <p>",
"    Chondroma accounts for 15 to 20 percent of benign rib tumors and presents as a slowly enlarging, painless mass. These neoplasms are usually located at the costochondral junction anteriorly and on radiographs show a small area of lytic bone with a sclerotic margin, making distinction from a low-grade chondrosarcoma difficult. Hence, these lesions are treated presumptively with wide excision, and local recurrence is reported. The most common sites of disease include the hands, femur, and humerus. This condition is the most common benign sternal tumor.",
"   </p>",
"   <p>",
"    Langerhans cell histiocytosis (also called eosinophilic granuloma) is more common in the skull than the ribs, but accounts for 10 to 20 percent of benign rib tumors. This condition is a diffuse inflammatory infiltrative process that affects males five times more frequently than females. Presentation is with localized chest wall pain as well as occasional fevers and malaise, and radiographs reveal an expansile rib lesion with irregular destruction of the cortex and new subperiosteal bone formation. Hence, confusion with malignancy or osteomyelitis is not uncommon. Excision provides both diagnosis and cure for isolated lesions. Low dose radiation therapy has been recommended for multiple",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inaccessible lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Malignant neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrosarcoma is the most common malignant chest wall tumor. It is located on the anterior chest wall (costochondral arches or sternum) and can arise from a degenerated chondroma. Presentation is usually as a slowly growing painful mass with a hard, fixed chest wall lesion; 10 percent of patients have lung metastases at presentation. Wide excision is recommended because of an increased risk of recurrence and metastasis following incomplete resection. Radiation therapy is recommended for unresectable or incompletely resected tumors. Five-year survival rates are between 70 and 90 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=see_link\">",
"     \"Chondrosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other malignant tumors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Askin tumor (also known as Askin-Rosai tumor) of the chest wall &ndash; These tumors are considered part of the neoplastic spectrum of Ewing",
"      <span class=\"nowrap\">",
"       sarcoma/peripheral",
"      </span>",
"      primitive neuroectodermal tumor (PNET), and they are included in the umbrella term Ewing sarcoma family of tumors or EFT. EFT tend to affect young patients and are more common in the pelvis, humerus, and femur than the chest wall, but EFT can arise in the chest wall in 6 to 15 percent of cases. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=see_link\">",
"       \"Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Clinical manifestations of Askin tumors include painless swelling (49 percent), a painful, palpable mass (43 percent), dyspnea (17 percent), and chest wall pain without mass (6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/105\">",
"       105",
"      </a>",
"      ]. Metastases are present in 25 percent at diagnosis. Radiographic features include bony destruction with lytic and blastic lesions, elevation of the periosteum with several layers of subperiosteal bone formation (\"onion skin\"), and a pleural effusion. Osteomyelitis is included in the differential diagnosis of these tumors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=see_link\">",
"       \"Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Treatment always involves a multimodal approach and generally includes multiagent chemotherapy combined with wide excision",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      external beam radiation therapy to control the primary tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/105-107\">",
"       105-107",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"       \"Treatment of the Ewing sarcoma family of tumors\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=see_link\">",
"       \"Radiation therapy for Ewing sarcoma family of tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Osteosarcoma &ndash; Osteosarcoma can affect the chest wall, but more commonly involves long bones. This tumor affects both old and young patients, presents as a rapidly enlarging painful mass, often has synchronous lung metastases, and requires chemotherapy in conjunction with surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=see_link\">",
"       \"Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=see_link\">",
"       \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Solitary plasmacytoma &ndash; Solitary plasmacytoma, an isolated form of multiple myeloma, can affect the ribs, typically presenting with pain and a lytic lesion. Radiation therapy usually provides local control, and these patients need to be followed for the development of systemic multiple myeloma which can occur in 45 to 75 percent of patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=see_link\">",
"       \"Diagnosis and management of solitary plasmacytoma of bone\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most of the chest wall abnormalities described above are easily diagnosed when patients present with more severe manifestations of the condition, it is not uncommon to encounter a patient with dyspnea of unknown etiology who may have a more subtle form of chest wall disease. One is often faced with a reduced total lung capacity (TLC) detected during pulmonary function testing and must make the distinction between subtle interstitial",
"    <span class=\"nowrap\">",
"     inflammation/fibrosis",
"    </span>",
"    and chest wall abnormalities. Clues to the effects of the chest wall on dyspnea (such as the presence of kyphoscoliosis, abdominal pathology, prior rib cage surgery, etc) are often present on physical examination but might not be elicited unless sought out and considered in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=see_link\">",
"     \"Approach to the patient with dyspnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8839?source=see_link\">",
"     \"Physiology of dyspnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary function testing usually reveals a restrictive ventilatory defect defined as a reduced TLC (",
"    <a class=\"graphic graphic_figure graphicRef59123 \" href=\"UTD.htm?31/12/31949\">",
"     figure 4",
"    </a>",
"    ). In contrast to patients with interstitial lung disease, the residual volume (RV) is often preserved or may be elevated in individuals with chest wall abnormalities. Respiratory muscle strength may be preserved or mildly decreased. Exercise capacity is often reduced, but desaturation with exercise is uncommon, contrary to what is frequently observed in patients with interstitial lung disease. However, in some conditions (eg, scoliosis), atelectasis may be present and be associated with hypoxemia. Patients with more severe restrictive ventilatory defects are at risk for hypoventilation and hypercapnia. The point at which hypercapnia develops varies among patients depending on the type of chest wall abnormality and other factors that affect chest wall compliance and respiratory muscle strength. When the vital capacity decreases to less than 40 percent of predicted, monitoring for hypercapnia is appropriate. High resolution computed tomography (HRCT) scan of the chest is very sensitive for most forms of interstitial lung disease and can be used to exclude that diagnosis if the differentiation between chest wall and interstitial lung disease remains uncertain after the history, physical exam, and pulmonary function tests are complete. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=see_link\">",
"     \"Overview of pulmonary function testing in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a diagnosis is reached, specific therapies may be indicated, or the patient may be reassured in knowing the cause and prognosis of the condition. Noninvasive positive pressure ventilation may avert endotracheal intubation in selected patients with chest wall disease who suffer acute respiratory deterioration (eg, due to respiratory failure or another superimposed process). However, these patients require careful monitoring in an intensive care unit and must be hemodynamically stable, alert, adequately oxygenated, and at low risk for aspiration of gastric contents. Noninvasive positive pressure ventilation may be of benefit for longer term support of chronic respiratory insufficiency due to diseases of the chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?23/58/24490/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=see_link\">",
"     \"Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H517636\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proper function of the respiratory pump depends upon the normal structure of the chest wall. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal structure and function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diseases that affect the bony portion of the chest wall and can result in respiratory compromise include ankylosing spondylitis, congenital deformities (eg, pectus excavatum), flail chest, kyphoscoliosis, fibrothorax, thoracoplasty, and chest wall tumors. In addition, abdominal processes (eg, morbid obesity, ascites) can alter chest wall function. (See individual sections)",
"     </li>",
"     <li>",
"      Clues that chest wall disease is contributing to dyspnea are often present on physical examination (eg, pectus excavatum, kyphoscoliosis, thoracoplasty) but might not be identified unless sought out and considered in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In individuals with chest wall abnormalities, pulmonary function testing may reveal a restrictive ventilatory defect defined as a reduced total lung capacity (TLC) (",
"      <a class=\"graphic graphic_figure graphicRef67150 \" href=\"UTD.htm?21/47/22270\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef59123 \" href=\"UTD.htm?31/12/31949\">",
"       figure 4",
"      </a>",
"      ). The degree of restriction depends on the type and severity of the chest wall abnormality and any co-existing neuromuscular disease. In contrast to patients with interstitial lung disease, the residual volume (RV) is often preserved. Desaturation with exercise is uncommon unless there are associated parenchymal or vascular changes. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with more severe chest wall disease are at risk for respiratory insufficiency. Monitoring for hypercapnia is appropriate when the vital capacity decreases to less than 40 percent of predicted",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      serum bicarbonate is elevated. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once a diagnosis is reached specific or supportive therapies (eg, decortication for fibrothorax, weight loss for obesity, control of ascitic fluid, noninvasive positive pressure ventilation for kyphoscoliosis with respiratory failure) may be indicated, or the patient may be reassured in knowing the cause and prognosis of the condition. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/1\">",
"      Lee-Chiong TL Jr. Pulmonary manifestations of ankylosing spondylitis and relapsing polychondritis. Clin Chest Med 1998; 19:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/2\">",
"      Rosenow E, Strimlan CV, Muhm JR, Ferguson RH. Pleuropulmonary manifestations of ankylosing spondylitis. Mayo Clin Proc 1977; 52:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/3\">",
"      Ayhan-Ardic FF, Oken O, Yorgancioglu ZR, et al. Pulmonary involvement in lifelong non-smoking patients with rheumatoid arthritis and ankylosing spondylitis without respiratory symptoms. Clin Rheumatol 2006; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/4\">",
"      Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/5\">",
"      Wiedemann HP, Matthay RA. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med 1989; 10:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/6\">",
"      Tanoue LT. Pulmonary involvement in collagen vascular disease: a review of the pulmonary manifestations of the Marfan syndrome, ankylosing spondylitis, Sj&ouml;gren's syndrome, and relapsing polychondritis. J Thorac Imaging 1992; 7:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/7\">",
"      Calin A. Ankylosing spondylitis. Clin Rheum Dis 1985; 11:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/8\">",
"      Romagnoli I, Gigliotti F, Galarducci A, et al. Chest wall kinematics and respiratory muscle action in ankylosing spondylitis patients. Eur Respir J 2004; 24:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/9\">",
"      Vanderschueren D, Decramer M, Van den Daele P, Dequeker J. Pulmonary function and maximal transrespiratory pressures in ankylosing spondylitis. Ann Rheum Dis 1989; 48:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/10\">",
"      Fisher LR, Cawley MI, Holgate ST. Relation between chest expansion, pulmonary function, and exercise tolerance in patients with ankylosing spondylitis. Ann Rheum Dis 1990; 49:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/11\">",
"      Se&ccedil;kin U, B&ouml;l&uuml;kbasi N, G&uuml;rsel G, et al. Relationship between pulmonary function and exercise tolerance in patients with ankylosing spondylitis. Clin Exp Rheumatol 2000; 18:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/12\">",
"      Elliott CG, Hill TR, Adams TE, et al. Exercise performance of subjects with ankylosing spondylitis and limited chest expansion. Bull Eur Physiopathol Respir 1985; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/13\">",
"      Grassino A, Gross D, Macklem PT, et al. Inspiratory muscle fatigue as a factor limiting exercise. Bull Eur Physiopathol Respir 1979; 15:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/14\">",
"      Dagfinrud H, Vollestad NK, Loge JH, et al. Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 2005; 53:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/15\">",
"      Feltelius N, Hedenstr&ouml;m H, Hillerdal G, H&auml;llgren R. Pulmonary involvement in ankylosing spondylitis. Ann Rheum Dis 1986; 45:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/16\">",
"      Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med 2005; 118:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/17\">",
"      Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/18\">",
"      van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/19\">",
"      Boulware DW, Weissman DN, Doll NJ. Pulmonary manifestations of the rheumatic diseases. Clin Rev Allergy 1985; 3:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/20\">",
"      Shamberger RC. Congenital chest wall deformities. Curr Probl Surg 1996; 33:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/21\">",
"      Urschel HC Jr. Poland syndrome. Semin Thorac Cardiovasc Surg 2009; 21:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/22\">",
"      Morgan NV, Bacchelli C, Gissen P, et al. A locus for asphyxiating thoracic dystrophy, ATD, maps to chromosome 15q13. J Med Genet 2003; 40:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/23\">",
"      Sarimurat N, El&ccedil;iolu N, Tekant GT, et al. Jeune's asphyxiating thoracic dystrophy of the newborn. Eur J Pediatr Surg 1998; 8:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/24\">",
"      Beales PL, Bland E, Tobin JL, et al. IFT80, which encodes a conserved intraflagellar transport protein, is mutated in Jeune asphyxiating thoracic dystrophy. Nat Genet 2007; 39:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/25\">",
"      Yerian LM, Brady L, Hart J. Hepatic manifestations of Jeune syndrome (asphyxiating thoracic dystrophy). Semin Liver Dis 2003; 23:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/26\">",
"      Friedman JM, Kaplan HG, Hall JG. The Jeune syndrome (asphyxiating thoracic dystrophy) in an adult. Am J Med 1975; 59:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/27\">",
"      Weber TR. Further experience with the operative management of asphyxiating thoracic dystrophy after pectus repair. J Pediatr Surg 2005; 40:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/28\">",
"      Davis JT, Long FR, Adler BH, et al. Lateral thoracic expansion for Jeune syndrome: evidence of rib healing and new bone formation. Ann Thorac Surg 2004; 77:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/29\">",
"      Davis JT, Heistein JB, Castile RG, et al. Lateral thoracic expansion for Jeune's syndrome: midterm results. Ann Thorac Surg 2001; 72:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/30\">",
"      Kaddoura IL, Obeid MY, Mroueh SM, Nasser AA. Dynamic thoracoplasty for asphyxiating thoracic dystrophy. Ann Thorac Surg 2001; 72:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/31\">",
"      Aronson DC, Van Nierop JC, Taminiau A, Vos A. Homologous bone graft for expansion thoracoplasty in Jeune's asphyxiating thoracic dystrophy. J Pediatr Surg 1999; 34:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/32\">",
"      Sirmali M, T&uuml;r&uuml;t H, Top&ccedil;u S, et al. A comprehensive analysis of traumatic rib fractures: morbidity, mortality and management. Eur J Cardiothorac Surg 2003; 24:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/33\">",
"      Liman ST, Kuzucu A, Tastepe AI, et al. Chest injury due to blunt trauma. Eur J Cardiothorac Surg 2003; 23:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/34\">",
"      Ullman EA, Donley LP, Brady WJ. Pulmonary trauma emergency department evaluation and management. Emerg Med Clin North Am 2003; 21:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/35\">",
"      Velmahos GC, Vassiliu P, Chan LS, et al. Influence of flail chest on outcome among patients with severe thoracic cage trauma. Int Surg 2002; 87:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/36\">",
"      Tzelepis GE, McCool FD, Hoppin FG Jr. Chest wall distortion in patients with flail chest. Am Rev Respir Dis 1989; 140:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/37\">",
"      Tanaka H, Yukioka T, Yamaguti Y, et al. Surgical stabilization of internal pneumatic stabilization? A prospective randomized study of management of severe flail chest patients. J Trauma 2002; 52:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/38\">",
"      Shackford SR, Smith DE, Zarins CK, et al. The management of flail chest. A comparison of ventilatory and nonventilatory treatment. Am J Surg 1976; 132:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/39\">",
"      Shackford SR, Virgilio RW, Peters RM. Selective use of ventilator therapy in flail chest injury. J Thorac Cardiovasc Surg 1981; 81:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/40\">",
"      Cullen P, Modell JH, Kirby RR, et al. Treatment of flail chest. Use of intermittent mandatory ventilation and positive end-expiratory pressure. Arch Surg 1975; 110:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/41\">",
"      Trinkle JK, Richardson JD, Franz JL, et al. Management of flail chest without mechanical ventilation. Ann Thorac Surg 1975; 19:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/42\">",
"      Marini JJ, Rodriguez RM, Lamb V. The inspiratory workload of patient-initiated mechanical ventilation. Am Rev Respir Dis 1986; 134:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/43\">",
"      Thomas AN, Blaisdell FW, Lewis FR Jr, Schlobohm RM. Operative stabilization for flail chest after blunt trauma. J Thorac Cardiovasc Surg 1978; 75:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/44\">",
"      BERGOFSKY EH, TURINO GM, FISHMAN AP. Cardiorespiratory failure in kyphoscoliosis. Medicine (Baltimore) 1959; 38:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/45\">",
"      McMaster MJ, Glasby MA, Singh H, Cunningham S. Lung function in congenital kyphosis and kyphoscoliosis. J Spinal Disord Tech 2007; 20:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/46\">",
"      Bergofsky EH. Respiratory failure in disorders of the thoracic cage. Am Rev Respir Dis 1979; 119:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/47\">",
"      Lisboa C, Moreno R, Fava M, et al. Inspiratory muscle function in patients with severe kyphoscoliosis. Am Rev Respir Dis 1985; 132:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/48\">",
"      Weber B, Smith JP, Briscoe WA, et al. Pulmonary function in asymptomatic adolescents with idiopathic scoliosis. Am Rev Respir Dis 1975; 111:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/49\">",
"      Newton PO, Faro FD, Gollogly S, et al. Results of preoperative pulmonary function testing of adolescents with idiopathic scoliosis. A study of six hundred and thirty-one patients. J Bone Joint Surg Am 2005; 87:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/50\">",
"      Takahashi S, Suzuki N, Asazuma T, et al. Factors of thoracic cage deformity that affect pulmonary function in adolescent idiopathic thoracic scoliosis. Spine (Phila Pa 1976) 2007; 32:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/51\">",
"      CARO CG, DUBOIS AB. Pulmonary function in kyphoscoliosis. Thorax 1961; 16:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/52\">",
"      Jones RS, Kennedy JD, Hasham F, et al. Mechanical inefficiency of the thoracic cage in scoliosis. Thorax 1981; 36:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/53\">",
"      Di Bari M, Chiarlone M, Matteuzzi D, et al. Thoracic kyphosis and ventilatory dysfunction in unselected older persons: an epidemiological study in Dicomano, Italy. J Am Geriatr Soc 2004; 52:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/54\">",
"      Shannon DC, Riseborough EJ, Kazemi H. Ventilation perfusion relationships following correction of kyphoscoliosis. JAMA 1971; 217:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/55\">",
"      NAEYE RL. Kyphoscoliosis and cor pulmonale; a study of the pulmonary vascular bed. Am J Pathol 1961; 38:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/56\">",
"      Mezon BL, West P, Israels J, Kryger M. Sleep breathing abnormalities in kyphoscoliosis. Am Rev Respir Dis 1980; 122:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/57\">",
"      Shneerson JM. The cardiorespiratory response to exercise in thoracic scoliosis. Thorax 1978; 33:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/58\">",
"      Kesten S, Garfinkel SK, Wright T, Rebuck AS. Impaired exercise capacity in adults with moderate scoliosis. Chest 1991; 99:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/59\">",
"      dos Santos Alves VL, Stirbulov R, Avanzi O. Impact of a physical rehabilitation program on the respiratory function of adolescents with idiopathic scoliosis. Chest 2006; 130:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/60\">",
"      Buyse B, Meersseman W, Demedts M. Treatment of chronic respiratory failure in kyphoscoliosis: oxygen or ventilation? Eur Respir J 2003; 22:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/61\">",
"      Hillberg RE, Johnson DC. Noninvasive ventilation. N Engl J Med 1997; 337:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/62\">",
"      Ellis ER, Grunstein RR, Chan S, et al. Noninvasive ventilatory support during sleep improves respiratory failure in kyphoscoliosis. Chest 1988; 94:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/63\">",
"      Leger P, Bedicam JM, Cornette A, et al. Nasal intermittent positive pressure ventilation. Long-term follow-up in patients with severe chronic respiratory insufficiency. Chest 1994; 105:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/64\">",
"      Hill NS, Eveloff SE, Carlisle CC, Goff SG. Efficacy of nocturnal nasal ventilation in patients with restrictive thoracic disease. Am Rev Respir Dis 1992; 145:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/65\">",
"      Carrey Z, Gottfried SB, Levy RD. Ventilatory muscle support in respiratory failure with nasal positive pressure ventilation. Chest 1990; 97:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/66\">",
"      Bach JR, Alba AS. Management of chronic alveolar hypoventilation by nasal ventilation. Chest 1990; 97:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/67\">",
"      Simonds AK, Parker RA, Branthwaite MA. The effect of intermittent positive-pressure hyperinflation in restrictive chest wall disease. Respiration 1989; 55:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/68\">",
"      Sinha R, Bergofsky EH. Prolonged alteration of lung mechanics in kyphoscoliosis by positive pressure hyperinflation. Am Rev Respir Dis 1972; 106:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/69\">",
"      Gonzalez C, Ferris G, Diaz J, et al. Kyphoscoliotic ventilatory insufficiency: effects of long-term intermittent positive-pressure ventilation. Chest 2003; 124:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/70\">",
"      Mart&iacute; S, Pallero M, Ferrer J, et al. Predictors of mortality in chest wall disease treated with noninvasive home mechanical ventilation. Respir Med 2010; 104:1843.",
"     </a>",
"    </li>",
"    <li>",
"     McCool FD, Rochester DF. Chest wall diseases. In: Textbook of Respiratory Medicine, 2nd ed, Murray JF, Nadel JA (Eds), WB Saunders Co, Philadelphia 1994. p.2524.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/72\">",
"      Phillips MS, Miller MR, Kinnear WJ, et al. Importance of airflow obstruction after thoracoplasty. Thorax 1987; 42:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/73\">",
"      Phillips MS, Kinnear WJ, Shaw D, Shneerson JM. Exercise responses in patients treated for pulmonary tuberculosis by thoracoplasty. Thorax 1989; 44:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/74\">",
"      Ando M, Mori A, Esaki H, et al. The effect of pulmonary rehabilitation in patients with post-tuberculosis lung disorder. Chest 2003; 123:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/75\">",
"      Ghoshal AG, Saha AK, Roy DJ, Ghosh S. Fibrothorax--problem, profile and prevention. J Indian Med Assoc 1997; 95:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/76\">",
"      Sinha P, Sarkar P. Late clotted haemothorax after blunt chest trauma. J Accid Emerg Med 1998; 15:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/77\">",
"      Barrett NR. The pleura: with special reference to fibrothorax. Thorax 1970; 25:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/78\">",
"      Bolliger CT, de Kock MA. Influence of a fibrothorax on the flow/volume curve. Respiration 1988; 54:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/79\">",
"      Petro W, Maassen W, Greschuchna D, et al. Regional and global lung function in unilateral fibrothorax after conservative therapy and decortication. Thorac Cardiovasc Surg 1982; 30:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/80\">",
"      Inci I, Oz&ccedil;elik C, Ulk&uuml; R, et al. Intrapleural fibrinolytic treatment of traumatic clotted hemothorax. Chest 1998; 114:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/81\">",
"      Vassiliu P, Velmahos GC, Toutouzas KG. Timing, safety, and efficacy of thoracoscopic evacuation of undrained post-traumatic hemothorax. Am Surg 2001; 67:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/82\">",
"      Landreneau RJ, Keenan RJ, Hazelrigg SR, et al. Thoracoscopy for empyema and hemothorax. Chest 1996; 109:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/83\">",
"      Yap JC, Watson RA, Gilbey S, Pride NB. Effects of posture on respiratory mechanics in obesity. J Appl Physiol 1995; 79:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/84\">",
"      Ray CS, Sue DY, Bray G, et al. Effects of obesity on respiratory function. Am Rev Respir Dis 1983; 128:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/85\">",
"      Chen Y, Horne SL, Dosman JA. Body weight and weight gain related to pulmonary function decline in adults: a six year follow up study. Thorax 1993; 48:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/86\">",
"      Pankow W, Podszus T, Gutheil T, et al. Expiratory flow limitation and intrinsic positive end-expiratory pressure in obesity. J Appl Physiol 1998; 85:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/87\">",
"      Farebrother MJ, McHardy GJ, Munro JF. Relation between pulmonary gas exchange and closing volume before and after substantial weight loss in obese subjects. Br Med J 1974; 3:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/88\">",
"      Ferretti A, Giampiccolo P, Cavalli A, et al. Expiratory flow limitation and orthopnea in massively obese subjects. Chest 2001; 119:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/89\">",
"      Dempsey JA, Reddan W, Balke B, Rankin J. Work capacity determinants and physiologic cost of weight-supported work in obesity. J Appl Physiol 1966; 21:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/90\">",
"      SHARP JT, HENRY JP, SWEANY SK, et al. THE TOTAL WORK OF BREATHING IN NORMAL AND OBESE MEN. J Clin Invest 1964; 43:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/91\">",
"      Hakala K, Mustajoki P, Aittom&auml;ki J, Sovij&auml;rvi AR. Effect of weight loss and body position on pulmonary function and gas exchange abnormalities in morbid obesity. Int J Obes Relat Metab Disord 1995; 19:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/92\">",
"      Biring MS, Lewis MI, Liu JT, Mohsenifar Z. Pulmonary physiologic changes of morbid obesity. Am J Med Sci 1999; 318:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/93\">",
"      Thomas PS, Cowen ER, Hulands G, Milledge JS. Respiratory function in the morbidly obese before and after weight loss. Thorax 1989; 44:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/94\">",
"      Refsum HE, Holter PH, L&oslash;vig T, et al. Pulmonary function and energy expenditure after marked weight loss in obese women: observations before and one year after gastric banding. Int J Obes 1990; 14:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/95\">",
"      Sugerman HJ, Fairman RP, Baron PL, Kwentus JA. Gastric surgery for respiratory insufficiency of obesity. Chest 1986; 90:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/96\">",
"      Wadstr&ouml;m C, M&uuml;ller-Suur R, Backman L. Influence of excessive weight loss on respiratory function. A study of obese patients following gastroplasty. Eur J Surg 1991; 157:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/97\">",
"      Dreher M, Kabitz HJ, Burgardt V, et al. Proportional assist ventilation improves exercise capacity in patients with obesity. Respiration 2010; 80:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/98\">",
"      ABELMANN WH, FRANK NR, GAENSLER EA, CUGELL DW. Effects of abdominal distention by ascites on lung volumes and ventilation. AMA Arch Intern Med 1954; 93:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/99\">",
"      Angueira CE, Kadakia SC. Effects of large-volume paracentesis on pulmonary function in patients with tense cirrhotic ascites. Hepatology 1994; 20:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/100\">",
"      Duranti R, Laffi G, Misuri G, et al. Respiratory mechanics in patients with tense cirrhotic ascites. Eur Respir J 1997; 10:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/101\">",
"      Berkowitz KA, Butensky MS, Smith RL. Pulmonary function changes after large volume paracentesis. Am J Gastroenterol 1993; 88:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/102\">",
"      Chao Y, Wang SS, Lee SD, et al. Effect of large-volume paracentesis on pulmonary function in patients with cirrhosis and tense ascites. J Hepatol 1994; 20:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/103\">",
"      Gilroy RJ, Mangura BT, Lavietes MH. Rib cage and abdominal volume displacements during breathing in pregnancy. Am Rev Respir Dis 1988; 137:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/104\">",
"      Chang SC, Chang HI, Chen FJ, et al. Therapeutic effects of diuretics and paracentesis on lung function in patients with non-alcoholic cirrhosis and tense ascites. J Hepatol 1997; 26:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/105\">",
"      Laskar S, Nair C, Mallik S, et al. Prognostic factors and outcome in Askin-Rosai tumor: a review of 104 patients. Int J Radiat Oncol Biol Phys 2011; 79:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/106\">",
"      Indelicato DJ, Keole SR, Lagmay JP, et al. Chest wall Ewing sarcoma family of tumors: long-term outcomes. Int J Radiat Oncol Biol Phys 2011; 81:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/107\">",
"      Shannon Orr W, Denbo JW, Billups CA, et al. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol 2012; 19:3816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/58/24490/abstract/108\">",
"      Shneerson JM, Simonds AK. Noninvasive ventilation for chest wall and neuromuscular disorders. Eur Respir J 2002; 20:480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4320 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-376D3087B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24490=[""].join("\n");
var outline_f23_58_24490=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H517636\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL STRUCTURE AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANKYLOSING SPONDYLITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Exercise tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Parenchymal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CONGENITAL DEFORMITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pectus excavatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Poland syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Asphyxiating thoracic dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FLAIL CHEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      KYPHOSCOLIOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Exercise tolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      THORACOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      FIBROTHORAX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ABDOMINAL PROCESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Exercise tolerance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Ascites",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      CHEST WALL TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Benign neoplasms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Malignant neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H517636\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4320\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4320|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/8/28800\" title=\"diagnostic image 1\">",
"      Cardiac compression pectus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4320|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/55/26494\" title=\"figure 1\">",
"      Chest wall volume vs pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/47/22270\" title=\"figure 2\">",
"      Pulmonary function histogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/47/3824\" title=\"figure 3\">",
"      Cobb angles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/12/31949\" title=\"figure 4\">",
"      Severity restrictive dz",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4320|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/62/31712\" title=\"picture 1\">",
"      Pectus excavat photo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4320|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/3/23611\" title=\"table 1\">",
"      Causes of scoliosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20761?source=related_link\">",
"      Abdominal compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16553?source=related_link\">",
"      Approach to the patient with dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37690?source=related_link\">",
"      Bone sarcomas: Preoperative evaluation, histologic classification, and principles of surgical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35450?source=related_link\">",
"      Chondrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37769?source=related_link\">",
"      Clinical presentation, staging, and prognostic factors of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=related_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/37/7770?source=related_link\">",
"      Epidemiology, pathology, and molecular genetics of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31382?source=related_link\">",
"      Imaging of pleural plaques, thickening, and tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3673?source=related_link\">",
"      Overview of breast disorders in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35769?source=related_link\">",
"      Overview of hyperkyphosis in older persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4952?source=related_link\">",
"      Overview of pulmonary function testing in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21527?source=related_link\">",
"      Pathogenesis of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25207?source=related_link\">",
"      Pectus carinatum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18071?source=related_link\">",
"      Pectus excavatum: Etiology and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21704?source=related_link\">",
"      Pectus excavatum: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/40/8839?source=related_link\">",
"      Physiology of dyspnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41543?source=related_link\">",
"      Practical aspects of nocturnal noninvasive ventilation in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25338?source=related_link\">",
"      Radiation therapy for Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3528?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23321?source=related_link\">",
"      Respiratory physiologic changes following spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/35/24121?source=related_link\">",
"      Secondary spontaneous pneumothorax in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/6/5222?source=related_link\">",
"      The effect of sleep in patients with neuromuscular and chest wall disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37065?source=related_link\">",
"      Treatment and prognosis of adolescent idiopathic scoliosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=related_link\">",
"      Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_58_24491="Conditions incorrectly diagnosed as syncope";
var content_f23_58_24491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76023&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions incorrectly diagnosed as syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders with partial or complete LOC but without global cerebral hypoperfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epilepsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic disorders including hypoglycaemia, hypoxia, hyperventilation with hypocapnia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vertebrobasilar TIA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders without impairment of consciousness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cataplexy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drop attacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Falls",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional (psychogenic pseudosyncope)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TIA or carotid origin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LOC: loss of consciousness; TIA: transient ischaemic attack.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24491=[""].join("\n");
var outline_f23_58_24491=null;
var title_f23_58_24492="Plasma endotoxin levels sepsis";
var content_f23_58_24492=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Plasma endotoxin levels in patients with sepsis syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Endotoxin &gt;5 pg/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Endotoxin &lt;5 pg/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        P-value&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age, years",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Documented infection (n = 77)",
"       </td>",
"       <td>",
"        37 (48 percent)",
"       </td>",
"       <td>",
"        40 (52 percent)",
"       </td>",
"       <td>",
"        NS&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram negative infection (n = 46)",
"       </td>",
"       <td>",
"        31 (67 percent)",
"       </td>",
"       <td>",
"        15 (32 percent)",
"       </td>",
"       <td>",
"        &lt;0.05&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram negative bacteremia (n = 33)",
"       </td>",
"       <td>",
"        24 (72 percent)",
"       </td>",
"       <td>",
"        9 (28 percent)",
"       </td>",
"       <td>",
"        &lt;0.05&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No infection (n = 16)",
"       </td>",
"       <td>",
"        7 (44 percent)",
"       </td>",
"       <td>",
"        9 (56 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No gram-negative infection (n = 47)",
"       </td>",
"       <td>",
"        13 (27 percent)",
"       </td>",
"       <td>",
"        34 (72 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gram positive infection (n = 19)",
"       </td>",
"       <td>",
"        2 (10 percent)",
"       </td>",
"       <td>",
"        17 (90 percent)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock (n = 46)",
"       </td>",
"       <td>",
"        29 (63 percent)",
"       </td>",
"       <td>",
"        17 (37 percent)",
"       </td>",
"       <td>",
"        &lt;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactate (mmol/L)",
"       </td>",
"       <td>",
"        6.8 &plusmn; 0.8",
"       </td>",
"       <td>",
"        3.9 &plusmn; 0.5",
"       </td>",
"       <td>",
"        &lt;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organ system failure",
"       </td>",
"       <td>",
"        2.1 &plusmn; 0.2",
"       </td>",
"       <td>",
"        1.3 &plusmn; 0.1",
"       </td>",
"       <td>",
"        &lt;0.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Survivors (n = 44)",
"       </td>",
"       <td>",
"        17 (39 percent)",
"       </td>",
"       <td>",
"        27 (61 percent)",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"     NS: not significant.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Guidet B, Barakett V, Vassal T, et al, Chest 1994; 106:1194.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24492=[""].join("\n");
var outline_f23_58_24492=null;
var title_f23_58_24493="Travel vaccines for SOT travelers";
var content_f23_58_24493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for travel-related vaccinations for solid organ transplant travelers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendations for adults",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendations for children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Routine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza-parenteral",
"       </td>",
"       <td>",
"        Yearly",
"       </td>",
"       <td>",
"        Yearly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza-intranasal*",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumococcal polysaccharide",
"       </td>",
"       <td>",
"        Recommended; booster after five years",
"       </td>",
"       <td>",
"        Administration at age&nbsp;two years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tetanus/diphtheria",
"       </td>",
"       <td>",
"        Recommended; booster every 10 years",
"       </td>",
"       <td>",
"        Recommended per CDC guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pertussis",
"       </td>",
"       <td>",
"        Recommended in combination with Tetanus and Diphtheria once",
"       </td>",
"       <td>",
"        Recommended per CDC guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Human papilloma virus",
"       </td>",
"       <td>",
"        Recommended when indicated",
"       </td>",
"       <td>",
"        Recommended per CDC guidelines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MMR*",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella*",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella zoster*",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Not applicable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Travel-related",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis A",
"       </td>",
"       <td>",
"        Recommended for travel to endemic regions; consider using IVIG for more immunocompromised patients",
"       </td>",
"       <td>",
"        Recommended per CDC guidelines, minimum age for first dose age 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatitis B",
"       </td>",
"       <td>",
"        Recommended when indicated",
"       </td>",
"       <td>",
"        Recommended per CDC guidelines, at birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meningococcal conjugate",
"       </td>",
"       <td>",
"        Recommended when indicated",
"       </td>",
"       <td>",
"        Recommended per CDC guidelines, minimum age for fist dose&nbsp;two months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rabies",
"       </td>",
"       <td>",
"        Recommended when indicated",
"       </td>",
"       <td>",
"        Recommended when indicated, any age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Japanese encephalitis",
"       </td>",
"       <td>",
"        Recommended when indicated",
"       </td>",
"       <td>",
"        Recommended when indicated, minimum for first dose age 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inactivated polio (IPV)",
"       </td>",
"       <td>",
"        Recommended when indicated",
"       </td>",
"       <td>",
"        Recommended when indicated, minimum age 2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oral polio (OPV)*",
"       </td>",
"       <td>",
"        Contraindicated in patients/family members",
"       </td>",
"       <td>",
"        Contraindicated in patients/family members",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Typhim Vi",
"       </td>",
"       <td>",
"        Recommended when indicated",
"       </td>",
"       <td>",
"        Recommended when indicated for &gt;6 years old",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S. typhi Ty21a*",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacille Calmette-Gu&eacute;rin*",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yellow fever*",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"       <td>",
"        Contraindicated",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Live, attenuated.",
"    </div>",
"    <div class=\"reference\">",
"     1. Centers for Disease Control and Prevention Adult Immunization Schedule 2009. Available at: file://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm. (Accessed December 25, 2009).",
"     <br>",
"      2. Kotton, CN, Ryan, ET, Fishman, JA. Prevention of infection in adult travelers after solid organ transplantation. Am J Transplant 2005; 5:8.",
"      <br>",
"       3. Kotton, CN, Hibberd, PL. Travel medicine and the solid organ transplant recipient. Am J Transplant 2009 ;9(Suppl 4):S273.",
"       <br>",
"        4. Jong, EC, Freedman, DO. Chapter 8: Advising Travelers with Specific Needs: The Immunocompromised Traveler. In: 2010 Health Information for International Travel (available at file://wwwnccdcgov/travel/yellowbook/2010/chapter-8/immunocompromised-traveleraspx). 2010 ed. Atlanta: Centers for Disease Control and Prevention; 2010.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24493=[""].join("\n");
var outline_f23_58_24493=null;
var title_f23_58_24494="Thoracolumbar scoliosis";
var content_f23_58_24494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62029&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thoracolumbar scoliosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior radiograph demonstrating right thoracolumbar scoliosis. The air-fluid level in the stomach confirms that the radiograph was taken with the patient standing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Susan Scherl.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24494=[""].join("\n");
var outline_f23_58_24494=null;
var title_f23_58_24495="Left vocal fold polyp B";
var content_f23_58_24495=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left vocal fold polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Identified in an elderly woman with longstanding hoarseness. The polyp is large enough to ball valve into the subglottic airway with inspiration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_58_24495=[""].join("\n");
var outline_f23_58_24495=null;
